






Disease modifiers are genes that when activated can alter the expression of a 
phenotype associated with a disease. This can be done directly through affecting the 
expression of another gene that is causing the disease, or indirectly by affecting other 
factors that contribute to the phenotype’s variability. Identification of disease 
modifiers is of great interest from both treatment and genetic counseling perspectives. 
We set here to develop computational approaches to identify and study disease 
modifiers. We focus on two research avenues for studying disease modifiers: (1) One 
aimed at identifying and investigating modifiers of cancer, a complex disease 
influenced by multiple genetic and environmental factors, and (2) the other focuses 
on the identification of disease modifiers for monogenetic disorders which involve a 
single disease causing gene.  
 
Towards the first aim of studying cancer modifiers we take four 
complimentary approaches. (a) First, we developed a computational approach to 
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identify metabolic drivers of cancer that when applied to colorectal cancer, 
successfully identified FUT9 as a gene that strongly modifies tumors aggressiveness. 
(b) Second, to study metabolic pathway-level modifications in cancer, we developed 
an algorithm that summarizes cancer modifications to generate pathway compositions 
that best capture cancer associated alterations, which, as we show, enhances cancer 
classification and survival prediction. (c) Third, to identify modifiers of cancer 
immunotherapy treatment, we developed a new computational approach that robustly 
predicts the response to immune checkpoint blockage therapy. (d) Fourth, to identify 
modifiers of cancer radiotherapy treatment we built a robust predictor of rectal 
cancer patients’ response to chemo-radiation-therapy (CRT), identifying a signature 
of genes that may serve a potential targets for modifying patients’ response to CRT. 
 
Towards the second aim of studying genetic modifiers of Mendelian diseases, 
we developed a computational approach for identifying a specific expression pattern 
associated with genes that are modifying disease severity. We show that we can 
successfully prioritize genes that are modifying disease severity in cystic fibrosis and 
spinal muscular atrophy, where we have identified a new modifier and validated it 
experimentally. 
 
As will become evident from reading my dissertation, my work has naturally 
focused on developing a variety of computational approaches to analyze research 
questions that were of interest to me. Obviously, my work has greatly benefited and 
has been significantly enriched by close collaboration with many experimental labs 
  
that have kindly embarked on testing the predictions made, and to whom I am 
indebted. In sum, we developed methods to identify and study disease modifiers for 
both cancer and Mendelian diseases.  The applications of these methods generates a 
few promising leads for advancing the treatment for these diseases and improving 
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My long term research interests are in the development of computational approaches 
to identify and investigate disease modifiers that may improve the treatment for these 
diseases. I aim to develop approaches that can be robustly validated (using existing 
data or experimentally) and that are easily interpretable for our experimental 
collaborators and potential users from the biological fields. 
In this dissertation I present five computational approaches, designed to answer five 
research questions with one common objective to identify factors that can modify the 
expression, severity and prognosis of a disease. My main research focus has been 
studying modifiers for cancer, with one exceptional project in which I investigated 
disease modifiers for monogenetic disorders. Each computational approach presented 
here utilizes computational tools via specific data representation, designed to 
particularly answer each research question considering the relevant data in 
availability. 
Initially, I was interested in cancer driver genes identification, a well-studied and 
important problem, for which the main obstacle is distinguishing the genes that are 
driving cancer from these that are just associated with it (termed ‘passenger’ 
alterations). To this end, I utilized Genome Scale Metabolic Modeling that enables 
perturbation simulations and can be used to prioritize (metabolic) genes alterations 
that results with the transcriptional profile observed in tumors (and may hence be 




As I became interested in the field of machine learning, a major part of my work was 
focused on developing machine learning solutions for biological problems that were 
interesting to me. For this, I investigated machine learning algorithms and data 
representation to solve different research questions; Studying pathway-level 
aggregation, I learned that aggregating gene expression via canonical pathway 
prohibits simple cancer classification.  I hence developed a data-driven algorithm that 
aggregates gene expression for pathway composition that optimally differentiate 
between healthy and tumor tissues, which also enables cancer survival prediction. 
Later on, I was interested in predicting response to cancer treatment. Studying 
checkpoint blockage therapy (ICB) response prediction, I learned that while a few 
central features (immune checkpoint genes) play a key role in these treatments, the 
expression of these genes is a poor predictor of response. I hence developed a 
predictor that compares the expression of pairs of immune activators and inhibitors 
genes that can robustly predict ICB response and can be easily transferred across 
datasets. Then, Working with Thomas Ried at the NCI, I learned that approximately 
one third of rectal cancer patients (currently treated with neoadjuvant chemo-radiation 
treatment (CRT) followed by surgery) are tumor-free after CRT and might be equally 
well treated by a “watch and wait” strategy instead of surgery. I hence developed a 
predictor of response to CRT that specifically spots those complete responders and 
can be used to identify patients that may be spared from unnecessary surgery. 
Finally, I became interested in disease modifiers for monogenetic diseases. I found 
that existing approaches require the utilization of large sequencing data, which is 




that can prioritize potential modifiers using healthy tissues gene expression by 
characterized genetic interactions patterns associated with such modifiers. 
In sum, I have been studying different disease aspects and developed computational 
approaches adjusted to each research question considering the data availability. 
Working in close collaboration with different experimental labs on each of these 
projects provided me a better understanding of the research questions, which 
motivated the computational approaches I developed to answer each question. I 
believe that much of this work can be used in future studies to advance the 
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Identification of cancer driver genes 
Major tumor sequencing projects have been conducted and initiated in the past few 
years to identify genes that are frequently mutated and thereby are expected to have 
primary roles in the development of tumor 1–3. Most common methods identify genes 
that are mutated more frequently than expected from the background mutation rate 4,5. 
Other methods attempt to identify genes that exhibit other signals of positive selection 
across tumor samples, such as a high rate of non-silent mutations compared to silent 
mutations 5,6. Nevertheless, driver genes mutated at low frequency are still difficult to 
detect with this approaches. Other methods hence attempt to identify genes that 
exhibit other signals of positive selection across tumor samples, such as a high rate of 
non-silent mutations compared to silent mutations 2,7 or a bias towards the 
accumulation of functional mutations (FM bias) 8. 
 
Genome-scale metabolic modeling (GSMM) approaches to study human metabolism 
and cancer 
A Genome Scale Metabolic Model (GSMM) is a computer program built around a set 
of reactions that comprise a metabolic network, accompanied by a mapping of genes 
and proteins to the reactions they catalyze within the network 9. GSMM of human 
metabolism has become feasible in recent years thanks to the publication of the first 
full-fledged genome-scale human metabolic models (Recon110,11). In addition to a 




of approximately 1500 metabolic genes through their encoded enzymes to these 
reactions, sub-cellular compartmentalization of processes and pathways, and 
manually curated reaction stoichiometry and membrane transporters. A key critical 
merit of GSMM modeling is that it does not require the explication of detailed 
enzymatic kinetic information (which is yet unknown on a network scale) as it 
describes the metabolic state of cells at steady state. GSMM enables the integration of 
omics data collected at specific conditions to provide a genome wide view of their 
corresponding metabolism; that is, the prediction of the likely metabolic fluxes across 
the network, including uptake and secretion rates, cell proliferation and more. 
GSMMs can also be used to predict the phenotypic effects of genetic and 
environmental perturbations on the cell’s flux distribution and viability. Such 
modeling studies have been employed in recent years to describe human metabolism 
10 in general and in cancer 12–16. 
 
Aggregating metabolic pathway information for cancer classification 
Metabolism is universally conceptualized through the abstraction of pathways, which 
are groups of enzymatic reactions thought to operate coherently 17. Undoubtedly, this 
abstraction is very useful and underlies many studies 18. Hu et al. 19 showed that 
changes in the aggregate expression of canonical metabolic pathways that occur in 
individual tumors are reproducible in independent samples of the same tumor. On the 
other hand, it has also been observed that the canonical pathways abstraction does not 
capture the complexity of the metabolic network in full; Bordbar et al. 20 recently 




parsimonious use of cellular components. They showed that it produces pathways that 
are more biologically plausible than the human defined ‘canonical’ pathways present 
in databases such as KEGG, EcoCyc, YeastCyc, and Gene Ontology.  
There has been a considerable interest in cancer classifiers that utilize network- and 
pathway-based meta-features 21–24. However, recent studies reported that many of 
these classifiers do not outperform models trained over single gene features 25–27.  
 
Checkpoint blockade  immunotherapy in cancer 
Cancer immunotherapy using immune-checkpoint blockade (ICB) has created a 
paradigm shift in the treatment of advanced-stage cancers. The promising 
antitumour activity of monoclonal antibodies targeting the immune-checkpoint 
proteins CTLA-4, PD-1, and PD-L1 led to regulatory approvals of these agents for 
the treatment of a variety of malignancies. Patients might experience clinical 
benefits from treatment with these agents, despite unconventional patterns of 
tumour response that can be misinterpreted as disease progression, warranting a 
new, specific approach to evaluate responses to immunotherapy. However, only a 
subset of patients benefit from these treatments, while others may incur 
considerable side-effects and costs. Hence, predicting the patients’ responsiveness 
to ICB is being extensively investigated in recent years. 
 
Predicting clinical outcome of cancer and identification of prognostic biomarkers 
It has been previously established that gene expression profiling can be used to 




breast cancer 28, predicting recurrence of treated patients 29 and predicting distant 
metastasis 30.  
In rectal cancer, many studies have attempted to identify a clinically useful and 
reproducible gene expression signature capable of predicting response to neoadjuvant 
chemo radiation treatment (nCRT) using microarrays 31–36. Most studies have focused 
on the identification of predictive signatures to distinguish “good” responders from 
“bad” responders and were primarily interested in the identification of patients who 
would benefit the most from nCRT and spare others from the potential toxicity of 
CRT. However, definition of “good” response to nCRT may not be straightforward; 
significant variations in definitions of responders and non-responders, in addition to 
the intrinsic subjectivity of these definitions, may be critical in this setting. Moreover, 
most of these studies include only few dozen of patients, perform the feature selection 
alongside with the training procedure and have very small test set. As a result, many 
of the identified signatures were found not reproducible and none these has been 
integrated into the clinic for prognostic use to this day 37. 
 
Identification of genetic modifiers for monogenetic disorders 
Strategies used to show the role of genetic factors in phenotypic expression are often 
classified into three categories depending on the type of data available 38: (1) 
Association studies of case-control data, which is the most widely used strategy in the 
search for modifier genes, probably as it requires sampling patients only, rather than 
collecting familiar data. In association studies, the distribution of marker genotypes is 




which require available data from affected siblings. Linkage analysis compares the 
number of alleles shared identical by descent by affected siblings between 
phenotypically-concordant and discordant sibling pairs 41,42. (3) Blind search - 
Systematic genome-wide screens, which consists in searching for the genetic factors 
involved in the phenotype of interest over the whole genome, to identify individuals 
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Chapter 1: Identification tumor modifying metabolic genes. 
Published as  “An integrated computational and experimental study uncovers FUT9 
as a metabolic driver of colorectal cancer”, Molecular Systems Biology 201744  
 
Introduction 
Altered metabolism is a core hallmark of cancer and yet, surprisingly, very few 
metabolic cancer genes are known to play a causal role in tumorigenesis. Here we 
present an integrated computational approach that combines a large-scale genomic 
analysis with a genome-scale metabolic modeling (GSMM) approach to identify new 
metabolic tumor suppressor genes. At the first step, our computational pipeline uses 
standard genomic approaches to identify potential candidates presenting tumorigenic 
molecular properties in patients’ tumors. In a second step, we present a new GSMM 
method that identifies a subset of these genes that are likely to play a causal role in 
transforming the metabolic state of healthy colon tissue to a cancerous one. Our 
analysis predicts FUT9, as a causal metabolic driver of advanced stage colon cancer 
whose inhibition is predicted to modify the tumorigenic metabolic state from that of 
early colorectal tumors to that of late ones. The experimental testing of FUT9 
inhibition reveals its complex dual role in this malignancy; while the knockdown of 
FUT9 enhances proliferation and migration of the bulk of colon cancer cells in 
monolayers, it suppresses colon cancer cells expansion in tumorspheres and inhibits 
tumor development in a mouse xenograft models, testifying on its context dependent 







An integrated genomic-modeling analysis predicts a modifying causal role of 
FUT9 in colorectal cancer 44 
We developed a two-step computational approach to predict metabolic tumor 
suppressors, that is, genes whose downregulation promotes cancer. Applied to 
study colon cancer, the first step employs a straightforward genomic analysis 
of the Cancer Genome Atlas (TCGA) database45,46 to identify metabolic genes 
that are downregulated in colorectal cancer (Figure 1A). Subsequently, we 
performed a novel metabolic modeling analysis to identify, among the genes 
identified as associated with tumorogenesis in the first step, those whose 
downregulation is indeed most likely to result in the metabolic alterations 
observed in colorectal tumors and thus are more likely to play an actual causal 
role in the transformation of normal to cancerous tissues (Figure 1B). A 
detailed overview of each step follows. 
Genomic identification of 34 candidate metabolic tumor suppressor genes in 
colorectal cancer: This step consists of three sub-steps that are applied 
sequentially, analyzing gene expression, Copy Number Variation (CNV), and 
survival data from 272 colorectal cancer samples and 42 matching healthy 
colon tissues samples in the TCGA45,46: (1) First, analyzing the 
transcriptomics data of these samples we identified 4593 genes that are 




test with multiple hypothesis correction (alpha=0.001)). (2) Second, 328 of 
these downregulated genes have significantly lower copy number in the 
tumors compared to the healthy samples (Q-values < 0.25). (3) Finally, a 
Kaplan Meier survival analysis further narrowed down this list to 177 
candidate tumor suppressors whose downregulation is negatively correlated 
with patient survival (and thus, likely to enhance tumor progression; see 
Methods, Figure 1A). Reassuringly, the resulting list includes several known 
colon tumor suppressors such as APC47,48, TCF7L249,50, MCC51,  PTEN 52,53, 
and SMAD4 54,55. It also includes 34 metabolic genes that are present in the 








Figure 1. Two-step pipeline for predicting metabolic tumor suppressors. (A) 
Genomic analysis of three types of data yields an initial list of potential tumor 
suppressors. (B) GSMM-based approach of the potential tumor suppressors 
identifies metabolic genes whose knockdown may play a causal role in 
tumorogenesis. 
FUT9 tumorigenic properties 
To predict metabolic genes whose downregulation may play a causal role in 




Metabolic Transformation Algorithm (MTA)56. This algorithm was previously 
developed and used to successfully identify life-extending metabolic genes in 
yeast 56 and is employed here for the first time to search for metabolic tumor 
suppressors in cancer.  MTA is a generic algorithm that aims to identify 
metabolic gene knockouts that are capable of driving a transformation from a 
given metabolic state to another, defined target state. The inputs to MTA are 
the pertaining transcriptomic measurements of these two given and targets 
states. Its output is a ranked list of metabolic genes whose inactivation has the 
potential to induce the transformation from the given to the target states 
(Methods)56. In our case, the given metabolic state is the healthy, non-
malignant state, and the target state is the cancerous one, and correspondingly, 
the inputs to the algorithm are a set of gene expression data from matched 
healthy and tumor colon samples.  
 
While the original publication of MTA has mainly focused on its testing and 
validation in a known collection of gene knockouts in microorganisms, it 
already showed that MTA correctly identifies fumarate hydratase as a gene 
whose knockdown may cause the metabolic transformations observed in 
HLRCC57,58.  We now tested and validated that MTA successfully identifies 
the knockdown of succinate dehydrogenase (SDH) as a likely cause of the 
metabolic alterations observed in hereditary paraganglioma59. To further test 
the ability of MTA to identify the genes that where knocked down in 




mined the literature to assemble a collection of 19 datasets of metabolic genes 
for which we found mouse or human gene expression data before and after the 
knockdown of each of these genes. For each of these knockdowns, we gave 
MTA these transcriptomics data as inputs and applied it to predict the most 
likely genes whose knockdowns may account for the transcriptomic changes 
observed in these experiments.  MTA correctly predicted the experimentally 
knocked down genes in 13 of the 19 cases studied in the top 20% of the 
predictions (binomial P-value = 5.8266e-06, and its performance remains 
robust at multiple threshold setting, Appendix), validating MTA’s predictive 
ability in mammalian tissues. 
   
We then turned to apply MTA to identify metabolic genes that, when 
downregulated, can transform a healthy tissue to a cancerous one.  We 
analyzed three independent transcriptomic datasets including 27 paired 
healthy/tumor samples from TCGA, 17 paired healthy/tumor samples from 
Khamas et al.60 and 32 paired healthy/adenoma samples from Sabates-Bellver 
et al.61. In the first step, we ran an MTA analysis on each pair of matched 
healthy and tumor gene expression samples, yielding a ranked list of genes 
according to their oncogenic transformation scores (OTS) (Methods). OTS 
scores denote the likelihood that a gene knockout in the healthy cells can 
transform their metabolic state to a cancerous one. Following that, in a second 
step, an aggregate OTS was assigned to each metabolic gene by considering 




scores of each gene across all three datasets analyzed. We additionally 
analyzed colon polyp data from Sabates-Bellver et al61, which includes 32 
matched healthy and polyp samples. This data enabled us to perform two 
complementary MTA analyses, one predicting metabolic genes whose 
knockdown may cause the transformation to the polyp state, and one 
predicting metabolic genes whose inactivation may cause a further malignant 
transformation into colon cancer. (Methods). 
  
The distribution of the resulting OTS scores of the 34 metabolic genes 
examined via these MTA analyses is presented in Table 1. While all 34 genes 
present genomic patterns that associate them with a tumorigenic state (using 
expression, copy number and survival data), only few are predicted by MTA 
to causally transform the metabolic healthy state to that of a cancerous one. As 
evident, only the knockdown of PTEN and FUT9 is predicted to transform the 
metabolic state of healthy cells as well as that of adenoma cells to that of 
colorectal tumors with high OTS scores (Methods). FUT9 is the most highly 
scored gene and is also strongly supported by the earlier genomic analysis: Its 
expression is strongly downregulated in colon cancer (Rank-sum P-value = 
1e-22, Figure 2A), it is significantly deleted in colon cancer while not in other 
cancer types (Q-value = 0.0356, Figure 2B), its low expression is associated 
with poor survival in colon cancer (Kaplan-Meier (KM) ∆AUC = -0.1206, 
Figure 2C) (Table 1) (The resulting KM log-rank P-value is 0.1942, likely due 




patients)). Interestingly though, while MTA highly scores FUT9 for all three 
transformations, FUT9 is not significantly downregulated at early stage colon 
adenomas using paired gene expression of healthy/adenoma samples from 
Sabates-Bellver et al.61 (Paired student t-test, P-value = 0.47, Appendix Figure 
S1). This suggests that its inactivation may play a significant role only at later 
stages of colon cancer progression. Bearing this observation in mind, we set to 







































































































































































Table 1. Predicted tumor suppressors properties. For each metabolic predicted 
tumor suppressor, the table displays: (1) the OTS scores for the three 




(3) Copy Number (CN) deletion Q-value (P-value that has been adjusted for 
the False Discovery Rate), and (4) Kaplan-Meier survival ∆AUC. 
 
GSMM analysis of the metabolic implications of FUT9 inactivation: FUT9 
belongs to the glycosyltransferase family and catalyzes the last step in the 
biosynthesis of Ley glycolipids in the carbohydrate antigen Lex62,63. This 
reaction takes place in the Golgi compartment, and the product is transported 
to the cytosol and secreted out from the cell64. The Ley glycolipid was 
previously reported to inhibit the procoagulant activity and metastasis of 
human adenocarcinoma65–67. The loss of FUT9 in the metabolic model 
prevents Ley glycolipid formation and secretion. To chart the network-wide 
metabolic alterations induced by FUT9 inactivation, we performed a 
Minimization Of Metabolic Adjustment (MOMA)68 analysis to predict the 
metabolic state after FUT9 KD in late stage  colorectal cancers, simulated by 
the Gene Inactivity Moderated by Metabolism and Expression (GIMME) 
algorithm 69 (Methods). This pinpoints reactions whose flux is predicted to be 
most afflicted by FUT9 inactivation in advanced stage cancer. We found that 
the loss of FUT9 in late stage colorectal cancers is predicted to cause an 
increase in the flux of 25 reactions, and a decrease in the flux of 6 reactions. 
The flux is predicted to increase in reactions associated with Glucose 
metabolism, and particularly TCA cycle (hyper-geometric P-value = 1.3676e-
09, Figure 2D). We find that the expression of metabolic genes associated 




regulated in stage 4 vs. stage 3 colon tumors when compared by their 
expression in TCGA data (hyper-geometric P-value = 0.0046). Experimental 
evaluation of these predictions using the Human Glucose Metabolism, RT² 
Profiler™ PCR Array revealed a good correlation with our computational 
prediction (Fig. 2D). In particular, 12 genes, including FH and SDHD proved 
to be upregulated in FUT9 silenced cells as expected from our computational 
analyses. 
 
To evaluate the effect of FUT9 knockdown (KD) and overexpression (OE) on 
biomass production, Glucose consumption, Lactate production and Oxygen 
consumption in the benign colon adenoma state, we (1) simulated the wild-
type metabolic state associated with colon adenoma. This was done by 
incorporating adenoma gene expression data from Sabates-Bellver et al.61 
using the GIMME algorithm.  (2) We then sampled 100 flux distributions in 
the resulting predicted adenoma wild-type state. In each such sample we 
applied the MOMA68 algorithm to predict the metabolic state after FUT9 KD 
and OE in adenoma, summing up the results overall 100 samples (Methods). 
We find that the biomass production predicted is significantly higher under 
FUT9 OE than its KD, as well as Lactate secretion rate (Wilcoxon rank-sum 
P-value = 0.0081 and 0.0173, respectively, Figure 2E). While Oxygen 
consumption rate is significantly higher under FUT9 KD (Wilcoxon rank-sum 
P-value = 6.79e-8, Figure 2E).  These predictions imply that FUT9 activity is 




consistent with the genomic findings we reported above that while FUT9 
expression is strongly downregulated in colon cancer is not significantly 
downregulated at early stage colon adenomas. 
 
We next evaluated the metabolic effects of FUT KD and OE in the colon 
tumor state. To this end we performed a similar analysis as described above 
for adenoma, while first inferring the likely metabolic state of colon tumors 
(Methods). Strikingly, we find that the predicted biomass production in the 
cancerous state is significantly higher under FUT9 KD than its OE (Wilcoxon 
rank-sum P-value = 0.0245, Figure 2F), and that lactate production rate is also 
increased under FUT9 KD (Wilcoxon rank-sum P-value = 0.0859, Figure 2F), 
opposite to the observed in simulated colon adenoma state. These predictions 
imply that the loss of FUT9, while hampering the growth of adenomas, is 
required for the proliferation of colon tumors, while its overexpression 
significantly reduces proliferation in that state. 
 
Given the opposite predicted effects of KD perturbation in colon adenomas vs. 
tumors, we performed an additional GSMM analysis to study whether FUT9 
inactivation at early colorectal cancer stages can induce the metabolic state 
observed at advanced tumors, or only its inactivation at late stages can induce 
this transformation. To this end we first inferred the likely metabolic state of 
advanced colorectal tumors using the GIMME algorithm69, as done above in 




loss if FUT9 in each of the four different stages of colorectal cancer 
progression, asking how similar is the metabolic state induced after the loss of 
FUT9 in each of these stages to the advanced, late cancerous state. The 
metabolic state after the KD of FUT9 in each stage-specific context was 
predicted using the MOMA algorithm68 (Methods). This analysis revealed that 
the loss of FUT9 at early stages does not bring the metabolic state close to that 
observed in advanced cancer. Rather, for the FUT9 loss to cause such an 
effect, it has to occur in later stages of the disease (Figure 2G). This indicates 
that FUT9 downregulation is a tumor-transformative event only if occurs at 
later stages of tumor progression. To study this further from a genomic 
perspective, we analyzed the correlation between FUT9 copy number and the 
copy number levels of known early and late genetic markers of colorectal 
cancer. We find that FUT9 expression levels negatively correlate with the loss 
of the early markers APC and MCC (Spearman rho = -0.1726 and -0.1707, P-
value < 0.05, respectively), while it is positively correlated with the loss of 
TP53, a marker of the advanced stage, 70,71 (Spearman rho = 0.1759, P-value 






Figure 2. Tumorigenic attributes of FUT9. (A) A boxplot describing the 
expression of FUT9 in tumor vs. healthy colon tissues. (B) Q-value for CN of 
FUT9 in 12 different cancer types, the dashed line represents a significance 
threshold of 0.25. (C) Kaplan-Meier survival curve for FUT9 expression (top 
and bottom 0.5 quartiles). (D) The TCA cycle and its associated enzymes that 























































































































































































































































































































































Increased in stage 4 (TCGA)
Increased by FUT9 KD (experimental)




FUT9 KD (yellow) and increase following FUT9 KD experimentally (green). 
(E) Boxplot showing the distribution of biomass production, Glucose 
consumption, Lactate production and Oxygen consumption in adenoma state 
when FUT9 is knocked-down (KD) and overexpressed (OE). (F) Boxplot 
showing the distribution of biomass production, Glucose consumption, 
Lactate production and Oxygen consumption in cancer state when FUT9 is 
knocked-down (KD) and overexpressed (OE). (G) Boxplots sowing the 
MOMA scores obtained by the knock-down of FUT9 in stages 1-4. (H) Upper 
panel: Colorectal Adenoma-carcinoma sequence. Middle panel: the emerging 
role of FUT9 in colorectal tumor progression. Lower panel: Correlation heat-
map of FUT9 copy number (CN) and early and late stage prognostic markers 
of colorectal cancer. 
 
Experimental work  
The experimental testing of these predictions shows that FUT9 plays a 
complex dual role in this malignancy. On one hand, the knockdown of FUT9 
enhances proliferation and migration of the bulk of colon cancer cells in 
monolayers, pointing to a suppressive role (Figure 3). On the other hand, its 
knockdown suppresses colon cancer cells expansion in tumorspheres and 
inhibits tumor development in a mouse xenograft models, testifying to a tumor 
promoting role (Figure 4). These results suggest that FUT9’s inhibition may 
have a differential effect on different types of tumor cells: its knockdown 
attenuates tumor initiating cells (TICs), which are known to dominate 
tumorspheres and early tumor seeding and growth, but promotes bulk tumor 
cells. In agreement, we find that FUT9 silencing decreases the expression of 




computational and experimental results testify that FUT9 acts first as an 
oncogene in TICs and enhances early stages of tumor formation, but later it 




Figure 3. Knockdown of FUT9 expression increases aggressiveness of colon 
cancer cells. (A) HCT116 and DLD1 control and FUT9 knockdown cells were 
A B
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seeded evenly in 96 well plates and the number of viable cells after 72 hours 
was analyzed using Resazurin absorbance reading. The graph represents the 
mean ± s.e. from three independent replicates normalized to the control cells. 
Six wells per replicate were analyzed. (B) The same cells from (A) were 
seeded in soft agar and cultured for 28 days. The number of colonies formed 
were quantified relative to the control cells. The mean ± s.e. from two 
independent replicates are represented. (C) The fold change in gene 
expression for the FUT9 knockdown and FUT9 overexpressing cells were 
analyzed using RT-qPCR. The graphs represent the mean ± s.e. fold change 
from three independent replicates. (D) HCT116 and DLD1 FUT9 knockdown 
cells were seeded at very low densities in a 24 well dish and cultured for 10 
days. The number of colonies formed in each well were counted. The graph 
represents the mean ± s.e. of two independent replicates. Three wells were 
analyzed per replicate. Representative images of one well for each condition 
are shown. (E) The same colony formation assay as in (D) was performed and 
analyzed using FUT9 overexpressing cells. Representative images for each 
condition are shown. (F) HCT116 control and FUT9 knockdown cells were 
each seeded to form a confluent monolayer. A scratch was made in each 
monolayer and the width of the scratch monitored by imaging the same areas 
of each scratch (2 per scratch) at the time of scratching (0h) and 24, 48 and 72 
hours later.  The graph depicts the mean ± s.d. of two independent 
experiments and represents the percentage of scratch open at each time point 




are shown at different brightness and contrast settings. (G) The wound-healing 
assay was performed with HCT116 control and FUT9 overexpressing cells 
and analyzed as in (F). The graph summarizes the mean ± s.d. of two 
independent experiments and represents a percentage of scratch open at each 
time point relative to the 0h point. For optimal presentation, individual scratch 
images are shown at different brightness and contrast settings. * P < 0.05, 
Student's t-test 
***Figure 3 and the work presented in it is generated by the Franco J. 
Vizeacoumar and his lab members 44 
 
Our genomic analysis revealed that, while FUT9 is strongly downregulated at 
later stages of colon cancer development, it is still present in colon polyps and 
early adenoma, indicating that FUT9 activity may be required at the initial 
stages of tumor initiation. Thus, while FUT9 downregulation benefits the bulk 
of tumor cells as shown above, its activity may support the subpopulation of 
cancer stem cells or tumor initiating cells (TICs) that play a central role in 
tumor development. To study this hypothesis, HCT116 with FUT9 
knockdown and matching control cells were cultured as tumorspheres, which 
are predominantly formed by TICs 72–75. Consistent with our expectations, 
FUT9 knockdown reduced expansion of HCT116 cells in tumorspheres, while 
FUT9 overexpression produced enhanced proliferation of tumorsphere-
forming cells (Figure 4A-B). On a molecular level, this was accompanied with 




Since OCT4 has been shown to support TIC formation 76,77, this observation 
provides a mechanistic explanation for FUT9 effect in supporting TIC 
activity. These results show that, in contrast to the anti-proliferative effects of 
FUT9 activity in the bulk of colon cancer cells (Figure 3A-D), FUT9 activity 
may actually be required for the efficient expansion of TIC populations. This 
was further confirmed by flow cytometry analysis, showing that FUT9 
silencing decreases the expression of a prominent colorectal cancer TIC 
marker CD44 72,78  in HCT116 cells (Figure 4C).  
Since TIC cells are essential for tumor initiation, tumor maintenance and 
tumor growth79–84, increased TIC activity is expected to accelerate tumor 
growth in vivo79,83,84. To test the effect of FUT9 on this process, we generated 
a xenograft model of colorectal cancer in immune-deficient NOD/SCID 
gamma mice. HCT116 cells with silenced FUT9 expression or control cells 
transduced with non-targeting shRNA were injected subcutaneously in equal 
numbers into the flank of the immuno-deficient mice and the growth of the 
resulting tumors was monitored. In agreement with its inhibitory effect in 
tumorspheres, FUT9 silencing also significantly reduced growth of xenograft 
tumors (Figure 4D). This may reflect the dual functionality of FUT9 where it 
supports tumor development by enhancing TIC activity (Figure 4E), while 





Figure 4. Expression of FUT9 supports tumor development. (A) HCT116 
FUT9 knockdown and matching control cells were seeded in ultra-low 
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collected, dissociated, and the total number of cells counted. The graph 
represents the mean ± s.e. of two independent replicates normalized to the 
number of control cells. Each replicate represented tumorsphere cells 
collected from 24 independent wells. Representative images are shown. Scale 
bar, 1000 µm. (B) FUT9 overexpressing and control cells were cultured as 
tumorspheres and analyzed as in (A). Two independent replicates and 
representative pictures are depicted. (C) CD44 expression in FUT9 
knockdowns (in red) and shRFP control (in blue) in HCT116 cells were 
assessed using anti-CD44 and flowcytometry and representative histograms 
were overlayed (second panel). Isotype controls were also plotted and 
overlayed (first panel). Median fluorescent intensity (MFI) values derived 
from the software are plotted as bar chart. The graph represents the mean ± 
s.e. of two independent replicates. (D) HCT116 FUT9 knockdown or control 
cells were injected subcutaneously into the right flank of NOD/SCID mice 
and monitored for tumor formation. Each tumor was measured using calipers 
and the mean volume for the FUT9 knockdown and control tumors were 
graphed (first panel). The graph represents two independent experiments with 
a minimum of 11 mice analyzed per experimental condition. Mean tumor 
volumes ± s.d. are shown. Upon experiment termination, tumors were 
extracted, weighed, and the mean tumor weights ± s.d. are shown in the 
second panel. (E) A schematic showing the abundance of FUT9 positive cells 




***Figure 4 and the work presented in it is generated by the Franco J. 
Vizeacoumar, Andrew Freywald and their lab members 44 
 
Methods 
Kaplan-Meyer survival analysis of potential tumor suppressors.  
For each gene found to be significantly lowly expressed and deleted through 
gene expression and copy number data, we applied Kaplan-Meyer survival 
analysis to examine the association of its downregulation with poor patient 
survival. We use TCGA COAD survival and gene expression data, and 
separate the expression of each gene to ‘high’ and ‘low’ bins by its median 
level. We calculate the ∆𝐴𝑈𝐶 resulting from the two Kaplan-Meyer curves 
and select only genes with ∆𝐴𝑈𝐶 < 0 indicating that their low expression is 
associated with poor survival. 
 
A constraint-based model of metabolism.  
A metabolic network consisting of 𝑚 metabolites and 𝑛 reactions can be 
represented by a stoichiometric matrix 𝑆, where the entry 𝑆!" represents the 
stoichiometric coefficient of metabolite 𝑖 in reaction 𝑗. A Constraint-Based 
Model (CBM) imposes mass balance, directionality and flux capacity 
constraints on the space of possible fluxes in the metabolic network's reactions 





𝑆 ∙ 𝑣 = 0 (1) 
𝑣!"# ≤ 𝑣 ≤ 𝑣!"# (2) 
 
Where 𝑣 is the flux vector for all reactions in the model (i.e. the flux 
distribution). The exchange of metabolites with the environment is 
represented as a set of exchange (transport) reactions, enabling a pre-defined 
set of metabolites to be either taken up or secreted from the growth media. 
The steady-state assumption represented in Equation (1) constrains the 
production rate of each metabolite to be equal to its consumption rate. 
Enzymatic directionality and flux capacity constraints define lower and upper 
bounds on the fluxes and are embedded in Equation (2). In the following, flux 
vectors satisfying these conditions will be referred to as feasible steady-state 
flux distributions.  Gene knockdowns are simulated by constraining the flux 
through the corresponding metabolic reaction to zero. Similarly, 
environmental perturbations are simulated by constraining the flux through 
the associated exchange reaction to zero.  
For each of the dataset analyzed here, we simulated the same media that was 
used in the experiment (DMEM). For modeling human metabolism we have 
used Recon1. 64 
 
Metabolic Transformation algorithm (MTA).  
MTA receives as input the gene expression measurement of two distinct 




the following steps: (1) determine the flux distribution that corresponds to the 
source state using integration Metabolic Analysis Tool (iMAT) ; (2) identify 
the set of genes whose expression have significantly elevated or reduced 
between the source and targets states, and the set of genes whose expression 
remained relatively constant between the states. Next, the algorithm searches 
for perturbations that can alter the fluxes of the changed reactions in the 
observed direction, while keeping the fluxes of the unchanged reaction as 
close as possible to their predicted source state. Finally, MTA outputs a 
ranked list of candidate perturbations according to their ability to transform 
from the source to the target metabolic state.  
 
The Transformation Score 
Relying on the optimization value obtained by MTA to rank the 
transformations induced by different perturbations is suboptimal, since the 
integer-based scoring of the changed reactions is coarse-grained and does not 
distinguish between solutions achieving large flux alterations and those 
obtaining flux changes barely crossing the 𝜀 threshold. Therefore, we chose to 
quantify the success of a transformation by a scoring function based on the 
resulting flux distributions rather than on the optimization objective values 
themselves. First, we denote the resulting flux distribution obtained in a given 
MIQP solution (for a given reaction knock-out) as 𝑣!"#. Second, reactions 
found in 𝑅! and 𝑅! are classified into two groups 𝑅!"##$!! and 𝑅!"#!$!"##, 




(forward or backward) or not. The following scoring function is then used to 
assess the global change achieved by the employed perturbation: 
          
!"# !!
!"#!!!







           (*)   
The numerator of this function is the sum over the absolute change in flux rate 
for all reactions in 𝑅!"##$!!, minus a similar sum for reactions in 𝑅!"#!$$%##. 
The denominator is then the corresponding sum over reactions in 𝑅! (the 
reactions which should stay untransformed). Following, perturbations 
achieving the highest scores under this definition are the ones most likely to 
perform a successful transformation by both maximizing the change in flux 
rate for significantly changed reactions, and minimizing the corresponding 
change in flux of unchanged reactions. Using an alternative scoring function 
based on the Euclidean distance instead of absolute values yielded similar 
results.  
While we believe that the TS score (Equation (*)) is the right one to pursue 
from a biological point of view, optimizing it directly is a very difficult 
mathematical task. To accomplish that one would need to develop a novel 
optimization algorithm for solving a mixed non-linear programming problem, 
whose objective function is non-smooth and non-differentiable, requiring non-
smooth optimization tools. Attempting such a solution directly would greatly 
complicate the problem as one would need to add many variables and 
constraints. Furthermore, the specific form of this ratio is actually dependent 
on the solution itself (as it evaluates 𝑅!"##$!! and 𝑅!"#!$$%## separately) 




chosen to take a two-step approach in this study that is sub-optimal but yet 
tractable. While the wild-type solution always achieves maximal values in 
terms of the original proxy objective function used in step 3 (by definition), it 
does not necessarily achieve high transformation scores (step 4). This is 
because the wild type solution is the least constrained, and hence most of the 
solutions found in step 3 can be satisfied by achieving only a minimal epsilon 
change; Those are obviously non-optimal from a biological standpoint as they 
do not really come close to the desired objective, and hence their TS score (in 
step 4) is sub-optimal in many of the cases, correctly ruling them out as 
biologically viable solutions. MTA analysis is established upon learning the 
regulatory effects of the knockdown of metabolic genes via the direct 
stoichiometric flux coupling of the reactions they encode to other reactions in 
the human metabolic network (which are inherently embedded in the reactions 
stoichiometric matrix it includes). 
 
Aggregated oncogenic transformation scores (OTS).  
MTA scores each reaction according to the extent of which its knockout is 
predicted to cause the observed transformation from normal to cancer. For 
each reaction  𝑖 (𝑅𝑋𝑁!) we define the aggregated OTS score by: 
 
𝑂𝑇𝑆(𝑅𝑋𝑁!) =    𝐼!"
!  ∈  !"#$!!"  !"#$%&





Where 𝐼!" is one when reaction 𝑖 was scores higher than random (MTA score 
when no perturbation is simulated) and zero otherwise. 𝑃(𝐼!" = 1) is a 
reaction’s probability to be scored higher than random in matched pair 𝑗 
(which is the number of perturbation that are scored higher then no 
perturbation in pair 𝑗). Thus, paired samples in which fewer reactions received 
a significant score are more heavily weighted.  
 
Reaction-to-gene mapping of OTS.  
OTS is assigned to each reaction in the metabolic model. Each metabolic gene 
is assigned the highest score assigned to one of its associated reactions, using 
the reaction-to-gene mapping defined by the Recon1 metabolic model. 
 
Colon polyp and colon tumor gene expression normalization.  
To apply MTA from polyp to tumor, we applied quantile normalization to the 
1496 metabolic genes present in Recon1 metabolic model.  We used 27 colon 
samples from TCGA that were used for the paired-MTA analysis and 32 colon 
adenoma sample, when the reference distribution is the mean expression of 
these 1496 metabolic genes across all 272 colon tumors in TCGA. 
  
Utilizing MOMA and GIMME algorithms to predict the pathway-level 
effect of FUT9 inactivation in late stage colon cancer.   
To investigate FUT9 role in tumorigenesis in the metabolic model, we set to 




late stage colon cancer. To this end, we utilized the GIMME algorithm to 
simulate metabolic flux of stage 3 colon tumors. To evaluate FUT9 effect on 
metabolic fluxes at that stage, we then utilize the MOMA algorithm and 
sample 100 flux distributions with and without FUT9 knockdown. For each 
reaction, we compare the MOMA sampled flux distributions with and without 
FUT9 KD using one-sided Wilcoxon rank-sum test. We define the set of 
reactions that are increased following FUT9 knockdown as reactions whose 
sampled flux is increased when FUT9 knockdown is simulated vs. WT 
(Wilcoxon rank-sum P-value<0.05) and the set of reactions that are decreased 
following FUT9 knockdown as reactions whose sampled flux is decreased 
when FUT9 knockdown is simulated vs. WT (Wilcoxon rank-sum P-
value<0.05).  
 
Utilizing the MOMA algorithm to evaluate the effect of FUT9 knockdown 
and over-expression on biomass production, Glucose consumption, 
Lactate production and Oxygen consumption.  
To predict the effect of FUT9 levels on Biomass production, Glucose 
consumption, Lactate production and Oxygen consumption we utilized the 
GIMME algorithm to simulate metabolic flux of (1) colon adenoma state 
using the 32 adenoma samples from Sabates-Bellver et al.61 (2) Colon cancer 
state using 268 cancerous samples from the TCGA. For each of the adenoma 
and cancer predicted flux distributions, we sampled 100 flux distributions for 




of FUT9 associated reactions to 80% of their maximum), using MOMA 
algorithm, aiming to minimize the metabolic adjustments after FUT9 
perturbations, from the initial adenoma or cancerous metabolic state. In both 
cases we set the lower bound of the biomass reaction to be at least 80% of its 
optimal rate to simulate proliferating cells and restrict variability in the 
resulting fluxes. 
 
Utilizing MOMA algorithm to predict stage specific context in which the 
loss of FUT9 is tumorigenic.  
To predict the context in which the loss of FUT9 drives the oncogenic 
transformation, we used colorectal cancer gene expression measurements 
from the TCGA database. For each sample, we predict a flux distribution 
using the GIMME algorithm69 (the mean flux distribution over 100 sample 
points was used) and the metabolic model in which FUT9 is knocked down. 
We then predict a flux distribution typical for stage 4 samples (using the 
GIMME algorithm69, genes are considered downregulated with FDR corrected 
P-value <0.05, compared to all other stages). Then, we compute the MOMA 
score obtained when aiming to minimize the metabolic adjustment from each 
sample to the metabolic state predicted for stage 4 samples. Finally, we 
compare the MOMA score distributions obtained for samples in each of the 
stages (1-4), describing for each such sample the extent to which the KO of 




stage 4. A similar analysis was repeated when using iMAT instead of GIMME 
to predict flux distributions, yielding similar results. 
 
Cell lines and transfections.  
HCT116 and DLD1 colon cancer cell lines were selected based on expression 
data for FUT9. Both cell lines were cultured in McCoy's 5A medium 
supplemented with (Fisher Scientific, SH3020001) supplemented with 10% 
(v/v) FBS (Life Technologies, 12483020), 100 units/mL penicillin-
streptomycin solution (Thermo Scientific, SV30010) at 37°C with 5% CO2. 
HEK293T cells were used to generate lentivirus and cultured in DMEM 
(Fisher Scientific, SH3024301) containing 10% (v/v) FBS and 100 units/mL 
penicillin-streptomycin at 37°C with 5% CO2. Cells were passaged using 
0.25% trypsin-EDTA at 70% confluency. 
Transfections were done using X-tremeGENE 9 (Roche, 6365809001) as per 
the manufacturer's instructions. Lentivirus was generated by transfecting 
HEK293T cells cultured in 100 mm dishes with psPAX2, pMD2.6, and 
pLKO.1-shRNA or pLX304 expression plasmids. Media was replaced after 24 
hours with DMEM containing 2% (w/v) bovine serum albumin (BSA) (Fisher 
Scientific, BP9703100) and lentivirus was harvested after 24 and 48 hours and 
pooled. 
To generate the FUT9 knockdown cells, HCT116 and DLD1 cells were 
transduced with lentivirus containing shRNA sequences specific to FUT9. 




separately or, in subsequent experiments, pooled and transduced together. An 
shRNA sequence specific to RFP (Sigma) was used as a non-targeting control. 
For each transduction, 0.5 mL of each shRNA lentivirus was added to 2x105 
cells in a 35 mm dish in a final volume of 3 mL with 8 µg/mL of polybrene 
(Sigma, 107689). Twenty-four hours after transduction, the media was 
removed and replaced with media containing 2 µg/mL puromycin (Fisher 
Scientific, BP2956100) for selection. Cells were selected for a minimum of 48 
hours before use in experiments. Knockdown cells were passaged a maximum 
of five times. The FUT9 overexpressing cells were generated by transducing 
HCT116 cells with lentivirus containing pLX304-FUT9 (DNA SU, 
HsCD00444887) using the same transduction method as above. After 
transduction, cells were selected using 4 µg/mL of blasticidin (VWR, 89149-
988) for 14 days. Cells were maintained with 1 µg/mL of blasticidin. 
 
Quantitative real-time PCR (RT-qPCR) analysis.  
RNA was isolated from cell pellets using RNeasy mini kit (Qiagen, 74104) 
according to the manufacturer’s instructions including DNase treatment 
(Qiagen, 79254). RNA quantification was performed using a NanoDrop 2000c 
spectrophotometer (Thermo Scientific) and RNA integrity was verified 
spectrophotometrically by A260/A280 ratios between 1.8 to 2.0 and 
A260/A230 ratios greater than 1.7. Equal quantities of RNA were used to 
generate cDNA using the RT2 First strand kit (Qiagen, 330401) according to 




FUT9 expression levels were evaluated using TaqMan real-time PCR gene 
expression assay (Life Technologies, 4369016 and 4331182, assay ID: 
Hs00276003_m1). The fold change in gene expression was analyzed using the 
∆∆CT method. Human Glycosylation-related gene expression was evaluated 
using RT2 Profiler human glycosylation PCR array (Qiagen, 330231 PAHS-
046ZA) according to the manufacturer’s instructions. Data analysis was 
performed using the ∆∆CT method as described in the manufacturer’s web 
portal (SABiosciences). 
 
Cell viability assay.  
Equal numbers of Fut9 knockdown and control cells were seeded in 96 well 
plates (5x103 cells per well). After 72 hours, the abundance of viable cells was 
analyzed using Resazurin (Fisher Scientific, AR002). Resazurin was added to 
each well at a concentration of 10% (v/v) and the plates were incubated at 
37°C and read using SpectraMax M5 microplate reader (VWR) after one, two, 
three, and four hours. An increased number of viable cells reflects increased 
cell expansion.  
 
Growth on soft agar.  
The ability of FUT9 knockdown and control cells to grow in low-anchorage 
conditions was determined by seeding cells in a soft agar medium. Cells were 
trypsinized and 2.5x104 cells suspended in 0.35% agar-media supplemented 




solution (Life Technologies, 11120052) and layered on a 0.6% agar-media 
bottom layer in 6 well plates. Cells were allowed to grow for 28 days and 
colonies were imaged using an EVOS FL Cell Imaging System microscope at 
40x magnification (Life Technologies) and the density of colonies was 
quantified using ImageJ software. 
 
Colony formation assay.  
The ability of individual cells to form colonies was shown by seeding a low 
density of cells (50 to 200 cells per well) in a 24-well culture plate. After ten 
days, the colonies were fixed with 100% cold methanol for 10 minutes and 
stained using 1% crystal violet. The numbers of visible colonies were counted. 
 
Wound-healing assay.  
Cells were cultured in 6-well plates and allowed to grow to a confluent 
monolayer. A scratch was made in each well by scraping with 100 µL pipette 
tip across the cell monolayer (time point zero of the experiment). Wells were 
rinsed with PBS three times to remove floating cells. The same areas of each 
scratch (2 per scratch) were imaged at the time of scratch (0 hours), 24, 48, 
and 72 hours using an EVOS FL Cell Imaging System microscope at 100 x 
magnification. The width of scratch in each image was measured using 
PowerPoint software. 
 




For tumorsphere culture, 2 x 103 cells from monolayer cultures were seeded 
into 96-well Ultra-Low attachment plates (Corning, 07-200-603) in complete 
Mammocult medium (Stemcell Technologies, 05620), prepared according to 
the manufacturer’s instruction. Cells were cultured for seven days, 
tumorspheres in each well were imaged with an EVOS FL Cell Imaging 
System microscope. Tumorspheres were then collected, dissociated, and cells 
were counted using a hemocytometer. For each replicate in this experiment, 
tumorspheres from 24 independent wells were collected into a 15 mL tube and 
centrifuged at 300 x g for 5 minutes. Collected tumorspheres were dissociated 
into a single cell suspension in 500 µL of pre-warmed Trypsin-EDTA. Cells 
were washed with tumorsphere culture medium containing 2% FBS and 
resuspended in serum-free tumorsphere culture medium for cell counting. 
 
Xenograft models.  
All animal experimental procedures were reviewed and approved by the 
University of Saskatchewan Animal Research Ethics Board. Mice used in the 
present study were from our established colony of NOD SCID gamma mice at 
the Laboratory Animal Services Unit (LASU), University of Saskatchewan. 
Mice were maintained at the LASU during the course of the experiments. 
Control shRFP and shFUT9 knockdown HCT116 cells were trypsinized and 
resuspended in ice cold PBS. Cells were mixed 1:1 with Matrigel (Corning, 
CB-40234) and 3 x 106 cells in a total volume of 100 µL and injected 




NOD/SCID gamma mice. At least five mice that developed tumors were used 
in our analysis for each experimental condition in each biological replicate. 
One of the mice in the control group was excluded from the analysis of the 
last two time points due to lethality. Tumors were measured every 3 to 4 days 
using a digital caliper, and the tumor volume was calculated using the tumor 
ellipsoid formula A/2*B2 where A and B represent the long and the short 
diameter of the tumor respectively. Upon experiment termination, tumors 
were extracted, fixed in 10% formalin, and weighed. 
 
FACS analysis.  
Cells were harvested and washed 3 times with ice-cold PBS containing 0.25% 
FBS. Cells were incubated with FITC-conjugated mouse-anti-human CD44 
antibody (BD, 555478) or FITC-conjugated mouse IgG2b antibody (BD, 
555742) for 30 min at 4ºC in the dark. Cells were then washed thrice with 
PBS, run through a Beckman Coulter CytoFLEX flow cytometer at 488 nm, 




We present a novel approach for identifying metabolic tumor suppressors that 
leads to the discovery of the complex, multi-faceted role of FUT9 in colon 
cancer. On the methodological side, we show here that a metabolic modeling 
MTA analysis can successfully identify metabolic genes that play a causal 




formed via a standard genome-wide analysis. Such an analysis may be thus 
performed to further identify causal metabolic cancer genes given any list of 
candidate cancer drivers emerging from a genomic analysis, in other cancer 
types.  
 
 The role of FUT9 in colorectal cancer appears to be rather complex. 
Our results indicate that FUT9 activity promotes the expansion of TICs, while 
its downregulation supports expansion and aggressiveness of bulk of tumor 
cells. TICs represent a higher proportion of the overall cell population in a 
tumor at earlier stages of tumor development. At later stages however, TICs 
are gradually outgrown by the rest of the tumor cells (Figure 4E), but they are 
still required for efficient tumor growth and maintenance79–84. Since our 
experimental data suggests that FUT9 provides an advantage for TIC 
populations, while its reduced activity benefits other tumor cells, its relative 
abundance should be expected to gradually drop with tumor progression, 
mirroring a decrease in the proportional representation of TICs. Notably, in 
accordance with that, we found that FUT9 expression is maintained in earlier 
tumors: colorectal polyps and colorectal adenoma at the levels observed in 
healthy colon tissue (studied in paired, matched samples; Appendix Figure 
S1), while FUT9 levels progressively decrease from the M0 to M1 stages 
(Appendix Figure S5). Reduced FUT9 expression at the M1 metastatic stage 
also matches our observations, suggesting that FUT9 downregulation 




that as tumors develop, FUT9 activity is switched off in the bulk of tumor 
cells to enhance their aggressiveness, which should negatively affect patient 
survival. In agreement, our computational analysis showed a positive 
correlation between FUT9 expression and survival of colorectal cancer 
patients.  
 
 This study is focused on the identification of tumor suppressor genes, 
as simulating a gene’s knockdown in the metabolic model is very well 
defined, while simulating the over-expression of genes is more complex and 
challenging. Thus, developing an MTA approach to identify causal metabolic 
oncogenes whose overexpression is transforming the metabolic state remains 
an open challenge. Cancer evolution usually involves a sequence of genetic 
and environmental events; indeed, while our computational analysis points to 
the central role that FUT9 plays in generating a tumorigenic metabolic state in 
colon cancer, we find that its role depends on the overall genomic context, 
such as the cell types in which it occurs and the staging of the tumors. In 
agreement, our experimental data reveal that, while FUT9 activity enhances 
OCT4 expression, and is essential for the formation of tumor initiating cells, it 
also show that FUT9 downregulation enhances the invasive behavior of bulk 
colon cancer cells, which hence contributes at later stages following tumor 






 Overall, our findings support a dual role for FUT9 in colorectal cancer. 
They suggest that it may act in this malignancy in a manner similar to the 
reported actions of the EphB2 receptor, a known hallmark of colorectal cancer 
TICs85 that is also downregulated to allow colorectal cancer tumor 
progression86. Our description of this complex action of FUT9 identifies an 
entirely new player in colorectal cancer and adds another intriguing member 
to the rather short list of metabolic genes that have been shown to play a 























Chapter 2: Cancer pathway modifiers. 
Published as “Data-driven metabolic pathway compositions enhance cancer survival 
prediction” PLOS Computational Biology, 2016 87 
Introduction  
 
Altered cellular metabolism is an important characteristic and driver of cancer. 
Surprisingly however, we find here that aggregating individual gene expression using 
canonical metabolic pathways fails to enhance the classification of noncancerous vs. 
cancerous tissues and the prediction of cancer patient survival. This supports the 
notion that metabolic alterations in cancer rewire cellular metabolism through 
unconventional pathways. Here we present MCF (Metabolic classifier and feature 
generator), which incorporates gene expression measurements into a human 
metabolic network to infer new cancer-mediated pathway compositions that enhance 
cancer vs. adjacent noncancerous tissue classification across five different cancer 
types. These data-driven pathways, in contrast to the canonical literature-based 
pathways, successfully generate clinically relevant features that are predictive of 
breast cancer patients’ survival in an independent dataset. 
Results 
MCF pipeline  
We first tested if the use of canonical pathways enhances the accuracy of cancer 
classification. We overlaid gene expression data derived from 3611 samples 
across ten datasets of five cancer types (including breast, lung, colon, prostate and 




defined in the RECON1 human metabolic model 10 and quantified the expression 
of every metabolic pathway based on the sum of the expression of all genes 
associated with this pathway (Methods, which in this case yields better 
performance than using the mean expression). We then trained SVM classifiers of 
cancer vs. adjacent noncancerous tissue samples using either the expression of 
individual metabolic genes (henceforth, MGE-SVMs) or human canonical 
metabolic pathways’ expression (Methods). Testing the classifiers in five-fold 
cross validation we found that using the canonical pathway expression leads to 
inferior performance in these classification tasks compared to using the individual 
metabolic gene expression. These findings motivated us to identify pathways 
whose activity may better reflect the altered rewiring of metabolism in cancer and 
enhance cancer prediction.  
To this end we developed a new data-driven algorithm, called the Metabolic 
classifier and feature generator (MCF): (1) We first define a differentially 
expressed reaction as a reaction whose ranked expression level within a sample is 
significantly different in noncancerous vs. cancerous samples (using a Wilcoxon 
rank-sum p-value with 𝛼 = 0.05, Methods). (2) The next step of MCF follows the 
concept of reporter metabolites 88 - it identifies metabolites that participate in 
differentially expressed reactions between the noncancerous and cancerous 
samples. (3-4) The key novelty of MCF is to use these reporter metabolites as 
centerpieces for building novel composite pathways leading from each reporter 
metabolite s to a group of target metabolites Ts that show consistent differential 




(by construction) predictive of the cancer vs. non-cancer states. (5) We then build 
a support vector machine (SVM-MCF) ensemble classifier of cancer vs. 
noncancerous tissue based on the gene expression of the new composite pathways 
as classification features. We apply a five-fold cross validation procedure to test 
the classification rate (accuracy) and area under the cover (AUC) for each dataset 
studied (Methods). The main steps of MCF are outlined below and in Figure 5 
(see Methods for a formal description): 
(1) Rank-transform the gene expression data: We first rank-transform the gene 
expression data and convert it biochemical reaction expression values using 
the human model’s genes-to-reactions mapping. This results in patient specific 
weighted metabolic networks in which the weights of each reaction edge 
correspond to the rank assigned to this reaction for a certain patient.  
(2) Identify seed reporter metabolites: For computational tractability, we limited 
the search to simple paths in which the first reaction is differentially expressed 
between the two states. To this end, we identify metabolites that are substrates 
in a large number of reactions that are differentially expressed between 
cancerous and noncancerous samples.  
(3) Assigning ‘expression weights’ from each seed reporter metabolite on the 
paths to all other metabolites in the network: We calculate the heaviest 
distances (i.e. the weight of a simple path with the largest sum of reactions’ 
expression values) from each seed metabolite to all other metabolites in the 
network. For the purpose of identifying the new composite paths, the 




representation having metabolite nodes and (directed) edge connecting any 
two metabolites that participate in a given reaction as a substrate and a 
product, respectively (if the reaction is directed).  
(4) Identify the most differentially expressed (‘heaviest’) pathways: For each 
source metabolite s we find the L=10 target metabolites Ts such that the 
heaviest distance from s leading to each of the targets in Ts differs most 
between the noncancerous and cancer training sets.  
(5) Building an SVM classifier: For each of the N source metabolites s we train 
an independent SVM classifier to distinguish cancerous from noncancerous 
samples using the weight of the L selected paths from s to Ts  as features. This 
results in an ensemble of N SVMs. A test sample is then classified by a 






Figure 5. Overview of the MCF algorithm.  
MCF predictive performance  
We compared the accuracy of the MCF to MGE-SVMs classifiers that are 
based on individual metabolic gene expression by comparing their AUC and 
mean accuracy scores in a five-fold cross validation on various cancerous vs 




MGE-SVM in all 10 datasets studied spanning five different cancer types, and 
significantly outperforms MGE-SVM in five of these datasets. 
 
As MCF aggregates transcriptional information in network-based manner, we 
hypothesized that it will be more robust than MGE-SVM when trained on data 
of the same cancer type but aggregated from multiple studies. To test this we 
merged the available tumor/tissue samples expression (rank-transformed, 
Methods) data from both GEO and TCGA, producing a combined dataset for 
each of the five different cancer types studied. We compared the performance 
(AUC and accuracy) of MCF and MGE-SVM on each of the five combined 
datasets using a standard five-fold cross-validation procedure. Combining 
datasets in this manner accentuated the higher predictive performance of MCF 
vs. MGE-SVM across all cancer types studied (Figure 6), including colon 






Figure 6. Comparing the performance of MCF to MGE-SVM across 
integrated cancer-type datasets. (A) A bar plot describing the predicted AUC 
obtained over the combined datasets of the same cancer type using a five-fold 
cross validation procedure for MGE-SVM (red bars) and MCF (blue bars) 
classifiers. AUC denotes the area under the curve. Error bars represent one 
standard deviation, and p-values are for a one-sided, paired-sample t-test for 
the AUC of each of the five folds. (B), (C) present the receiver operating 
characteristic (ROC) curves obtained in the classification of the lung and 
breast cancer combined datasets, respectively.  
p = 7.81E-04 p = 0.002
p = 0.005 p = 0.001 p = 0.019
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Notably, source metabolites that strongly differ in usage between 
noncancerous and cancerous tissues may constitute interesting cancer 
biomarker candidates. We find that there is a small set of such source 
metabolites that recur in multiple cancer types, and they vanish in randomly 
shuffled data. These include currency energy metabolites (e.g., NAD+ and 
ATP), a finding consistent with the large alterations seen in energy 
metabolism in cancer. We examined the target metabolites Ts that contribute 
most to ATP being differentially utilized.  As the paths leading to them from 
ATP are most differentially expressed, this may testify that the consumption 
of ATP to produce each of these metabolites is altered in cancer (and may 
possibly serve as correlate to their overall production levels). These target 
metabolites are specific for cancer type (Table 1, a pattern that remained 
robust to the introduction of noise to the data (See Methods). This suggests 
that while ATP is differentially utilized between tumors and their 
noncancerous tissues counterparts in all cancer types, there exists considerable 
variance in the ways it is utilized. 
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carboxamide        ↓ UDP                             
↑ Phospho 
enolpyruvate       
    
↑ 
Leukotriene 
B4        ↓ Oxalate                   
 
 
Table 2. Target metabolites selected for MCF. The target Ts metabolites that 
MCF selected when it choses ATP as a seed (↑ denotes increased formation 
from ATP in cancer and ↓ denotes decreased formation from ATP in cancer 
compared to noncancerous tissue counterpart, Methods). The table shows one 
instance of each selected target although in some cases the same target 
metabolite was identified in multiple compartments (e.g. UDP in the cytosol 
and in the mitochondria).  
  
Several of the target metabolites are known to be associated with their 
respective cancers: Oxalate has been studied as a survival marker in lung 
cancer 89; spermine has been observed to be differentially expressed in lung 
and colon cancer 90–92; Carnitine was shown to slow down tumor development 
in colon cancer 93; and blockage of Leukotriene B4 was reported to suppress 




metabolites that take part in metabolic processes that are altered in the specific 
cancers they occur. 
 
MCF prediction of patients’ survival 
As we have shown, MCF generates new composite pathways that show more 
power than traditional pathways in classifying normal versus cancer samples. 
To evaluate the clinical significance of these new features we examined 
whether they are also predictive of a different objective, the prediction of 
survival of breast cancer patients. Furthermore, to test whether the clinical 
utility of MCF pathways carried between datasets, we trained and tested the 
pathways on independent datasets. For training we used the combined GEO 
and TCGA breast cancer data. For testing, we used an independent dataset 
(METABRIC, 95) that includes gene expression measurements from 1,981 
cancer patients and their corresponding survival information. Remarkably, we 
find that out of the 80 pathways that MCF identified as differentially 
expressed in the original classification task on the combined TCGA and GEO 
data (L=10 targets from 8 identified source metabolites), 58 pathways are 
predictive for survival in the METABRIC data using Kaplan-Meier estimator 
96 (FDR corrected Kaplan-Meier log-rank p-value < 0.05; methods). In 
marked contrast, the expression levels of none of the canonical metabolic 
pathways defined by Recon1 are predictive of survival in this dataset. This is 




metabolic pathways is not helpful in distinguishing between cancerous vs. 
noncancerous samples.  
 
To evaluate the aggregate predictive power of the set of pathways selected by 
MCF as a whole, we compared patients predicted by MCF to have the best 
and worst prognosis (top and bottom 10%, respectively; Methods) and found 
that they indeed have a marked difference in their survival as predicted 
(Figure 7A, delta-AUC = 0.2436, and Kaplan-Meier log-rank P-value < 1.0e-
30). In contrast, when aggregating information across the canonical human 
metabolic model pathways in a similar manner we find that pathways 
predicted to have best and worst prognosis show no difference in survival  
(Figure 7B, delta-AUC = 0.0176, and Kaplan-Meier log-rank P-value = 
0.4282). We then examined whether the aggregated pathway score can be 
used as a survival model for the METABRIC dataset, using the conventional 
concordance index (C-index) 97. We find that while the pathways selected by 
MCF are predictive of patients survival, the canonical human metabolic model 
pathways do not show such predictive power (C-index = 0.69 vs. 0.52, 
respectively). Interestingly we find that the predictive power of individual 
MCF selected pathways in the original task of predicting cancer vs. 
noncancerous samples (i.e. the AUC obtained from the cross validation 
procedure on the combined datasets from TCGA and GEO) markedly 
correlates with their predictive power for survival in the METABRIC dataset 




power across these different tasks and datasets, and further testifies to their 
clinical significance. 
  
Finally, we performed a canonical pathway enrichment analysis over the 
reactions participating in the MCF composite pathways identified in breast 
cancer that are predictive of survival. We find that the most enriched 
canonical pathways emerging in this analysis are already known to be 
associated with cancer initiation and progression, such as fatty acid related 
metabolic pathways 98–100, the citric acid cycle 101,102 and cholesterol and 
steroid metabolism 103 (Figure 7D). Hence, even though aggregated gene 
expression through canonical pathways does not show survival predictive 
power, the composite alterations in cancer do rewire its metabolism using 






Figure 7. MCF survival prediction. MCF pathway utilization predicts the 
survival of breast cancer patients, while canonical pathways show no such 
signal. Shown in (A) and (B) are the Kaplan-Meier survival curves for 
patients predicted by MCF and canonical pathways respectively to have the 
best and worst prognosis (top and bottom 10% of patients scores, respectively; 
Methods). (C) A scatter plot showing the correlation between the prediction 
classification accuracy achieved using each individual MCF pathway in the 
combined breast cancer data from TCGA and GEO (where they are identified) 
(X-label) and the C-index obtained using each such pathway in predicting 















































p < 1.0e-30 p = 0.4282
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patients’ survival on the (unseen) METABRIC data. (D) The canonical 
pathway enrichment of the reactions participating in the MCF composite 
pathways predictive of survival. The dashed line represents a significance 
threshold of 0.05 (corrected for multiple hypotheses testing). 
 
Methods 
Gene expression datasets  
We focused on five cancer types, and for each one utilized datasets from 
TCGA 45 and GEO 104, as summarized in Table 3. 
 






(N/C)  GEO accession 
sample count 
(N/C)  
Prostate  PRAD  487/52 GSE32448 105 40/40 
Lung adeno-
carcinoma 
 LUAD  58/490 GSE19804 91 60/60 
Colon  COAD  41/273 GSE32323 60 17/17 
Head&neck 
 HNSC  43/498 GSE6631 106 22/22 






Table3. Summary of the datasets utilized for five cancer types. N and C stand 
for number of normal and cancerous samples in the data, respectively. 
 
 
In addition, we used the METABRIC breast cancer database by Curtis et al. 95 
to test the predictive power of MCF pathways with respect to patient survival. 
 
Evaluation of classifiers 
Throughout this study, we evaluate classifier performance by computing the 
AUC and average accuracy in a five-fold cross-validation procedure. We 
repeated 100 times the following: 
• Down-sample either the cancerous or normal groups: Assume that the 
data has N normal samples and C cancerous samples and |N|>|C|. We 
randomly chose |C| samples out of the normal group and excluded the 
rest. Similarly, if the data had more cancerous samples than normal 
ones, we down-sampled the cancerous group to the size of the normal 
group. This ensures that the accuracy statistic is not biased due to an 
over-representation of one of the groups, which occurs in many of the 
datasets studied here. 
• 5-fold cross validation: We split the chosen samples into 5 folds, each 
time training on 4/5 of them and testing by computing the AUC or 





The AUC and accuracy shown here is the average of the 100 repetitions, and 
the paired t-test p-values are from the resulting vector of 100 AUC or 
accuracy values for each such random selection. 
 
Metabolic gene expression SVMs (MGE-SVMs)  
To classify cancer vs. normal samples according to metabolic gene 
expression, we trained a support vector machine (SVM) using the expression 
of 1,496 metabolic genes as features. We denote these machines MGE-SVMs. 
Metabolic genes are defined in this study as the set of 1,496 genes annotated 
in Recon1 10 a well-curated reconstruction of the global human metabolic 
network.  
We observed that SVMs trained on this reduced set of gene expression 
features consistently outperformed SVMs trained on the expression of all 
genes. This is not surprising seeing that the metabolic subset has roughly one-
order of magnitude smaller dimensionality, and yet remains highly 
informative because of the key role of metabolic adaptations in cancer 108–110. 
Applying further dimensionality reduction on the set of 1,496 metabolic genes 
(e.g., through PCA) had little effect on the results. In addition, we observed 
that training MGE-SVMs with ranked expression values (that we use for 
MCF) achieves similar, but slightly inferior, results to the ones obtained using 





Converting gene expression into biochemical reaction expression  
Recon1 defines a mechanistic genotype-phenotype relationship through 
Boolean rules that encode gene-protein-reaction (GPR) associations. To 
convert ranked gene expression to biochemical reaction expression, we 
evaluated the Boolean GPR rule of that reaction while replacing the “AND” 
and “OR” operators with “min” and “max”, respectively as described in 111. 
Differential expression between biochemical reaction is determined by a 
Wilcoxon rank sum test with a significance threshold of 0.05, Bonferroni-
adjusted for multiple hypotheses where appropriate. 
 
Computing metabolic pathway expression  
Classification based on metabolic pathways relied on the pathway definitions 
embedded in Recon1, which associates every reaction with a single pathway 
out of a total of 99 pathways defined based on the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) LIGAND database. To compute a pathway 
expression, we first converted the ranked gene expression to ranked reaction 
expression as described above, and then summed the ranked expression of all 
the reactions associated with the pathway. An alternative methods of 
computing pathway in which for each pathway we use the sum the ranks of all 
its associated genes showed inferior performance comparing to the method 
presented here, as well as using the mean of ranked reaction expression 





Identifying seed reporter metabolites  
MCF builds metabolic pathways that have highly differential expression 
between the two target states (i.e., cancerous and non-cancerous). However, 
identifying the most differentially expressed pathways between two groups of 
weighted networks is a NP-hard problem by reduction from the problem of 
finding the longest-path 112 (Given a directed weighted graph G, let w be the 
smallest weight in G. Create a copy G’ of G with all edge weights set to w-c 
for some constant c>0. The most differentiating path between G and G’ is the 
heaviest (i.e., longest) path in G). For computational tractability, we limited 
the search for simple paths in which the first reaction is differentially 
expressed between the two states. We chose source metabolites that are 
substrates in at least k>=5 differentially expressed reactions with Wilcoxon 
rank-sum p-value corrected for multiple hypothesis.    
 
Building the classifier 
To build a classifier based on the differential expression of the pathway from 
source metabolite s to L=10 target metabolites, we do the following: we 
compute the heaviest distances (i.e. the weight of a simple path with largest 
sum of reactions expression values) from s to the all other metabolites in the 
network in all of the train samples. For the purpose of computing paths, we 
followed the common approach 113,114 transforming the hypergraph into a 
digraph and limiting ourselves to pathways that are simple directed paths in 




metabolite nodes and a directed edge (u,v) connecting any two metabolites 
such that u and v participate in some reaction as a substrate and a product, 
respectively. We then select a set Ts of L target metabolites for which the 
paths from s were most differentially expressed. I.e., for every target 
metabolite t we compute the Wilcoxon rank sum p-value when comparing the 
heaviest distance from s to t in the normal vs. the cancer samples, and we 
finally choose the Ts with L metabolites that obtained the smallest p-values 
out of all possible targets. The distances from s to the chosen L metabolites 
(denoted Ts) are used as features for an SVM.  
 
Let N be the number of source metabolites detected. MCF repeats the 
procedure described above for each of the source metabolites s, and for each s 
a distinct SVM is trained. This results in an ensemble of N SVMs. A test 
sample is then classified by the majority vote of the N individual classifiers 
(no ties ever occurred in the present study). 
 
MCF classification score 
The MCF classifier is an ensemble of N SVMs (for each detected source 
metabolite). The MCF classification score for classifying observation 𝑥 is the 
sum of N scores assigned to 𝑥 by the N SVMs. Therefore: 







Where 𝑓! 𝑥  is the predicted response of 𝑥 for the trained classification 
function 𝑓! (trained on the features selected for source metabolite 𝑖) 
𝑓! 𝑥 =    𝛼!,!
!
!!!
𝑦!,!𝐺 𝑋! ,𝑋 + 𝑏! 
Where (𝛼!,!…𝛼!,!, 𝑏!) are the estimated parameters, 𝐺 𝑋! ,𝑋  is the dot product 
in the predictor space between 𝑋  and the support vectors and the sum indicates 
training set observations. 
 
Predicting patient survival by canonical or MCF pathways 
To train the model and select the features we use the combined GEO and 
TCGA breast cancer datasets and train it on the original classification task of 
separating noncancerous from cancer tissues (when all samples are used). This 
results in 80 composite pathways that are generated and selected by MCF (for 
comparison, the human metabolic network defines 99 different pathways). We 
then use the METABRIC dataset and calculate the weights of the 80 selected 
pathways for this dataset (by generating a weighted metabolic graph for each 
sample in the MTABRIC dataset and calculating the heaviest distance 
between each seed metabolite and the target metabolites selected for it for the 
combined dataset from GEO and TCGA) as well as the weight of the 99 
human metabolic network pathways. In the two pathways sets, we define the 
weight of each patient for every pathway by the sum of ranks of the reactions 
associated with the pathway. For every pathway we evaluated the KM log-





To calculate an aggregated pathway score using either the 80 MCF selected 
pathways or the 99 canonical model pathways we calculate the weights of 
these pathways using the METABRIC gene expression data. We compute for 
each patient’s tumor two aggregate scores (one over the MCF pathways and 
over the model pathways) as follows:  
 





When 𝑤𝑒𝑖𝑔ℎ𝑡!(𝑝) is the weight of pathway p for patient i. 𝑃! is the set of 
pathways (either MCF selected pathways of canonical pathways) in which 
high expression levels were associated with cancer state, and 𝑃! is the set of 
pathways in which high expression levels were associated with noncancerous 
healthy state. Both 𝑃! and 𝑃! are determined by analyzing the two breast 
cancer datasets from TCGA and GEO (the mean of each pathway was 
evaluated for noncancerous and cancer samples to decide whether a pathway 
is in 𝑃! or in 𝑃!). These 𝑃! and 𝑃! set of pathways were then used to predict 
the patients survival an independent METABRIC breast cancer dataset, by 
assessing 𝑤𝑒𝑖𝑔ℎ𝑡!(𝑝) for every sample based on its transcriptomics and 
computing 𝑠𝑐𝑜𝑟𝑒 𝑝𝑎𝑡𝑖𝑒𝑛𝑡!   accordingly. A KM analysis is then employed to 






MCF Robustness to gene expression noise 
To test MCF’s robustness, we introduced noise into every sample’s gene 
expression vector by adding random Gaussian noise with distributions N(0,1), 
N(0,2) and N(0,3). We then trained MCF classifiers based on the perturbed 




We present a novel method termed MCF that identifies data-driven pathway 
compositions that best differentiate the metabolic alterations occurring in 
cancerous vs. noncancerous tissues.  MCF leverages a priori knowledge on the 
structure of the human metabolic network (ignoring its conventional 
decomposition to canonical pathways) to inform the analysis of cancer vs. 
noncancerous gene expression. It detects key hubs of metabolic alterations 
and infers the composition of non-standard pathways altered in a specific 
cancer type. Applied across five different cancer types, we find that MCF 
outperforms standard methods in the basic task of cancer vs. noncancerous 
classification. Remarkably, MCF derived pathways successfully predict 
patients’ survival in an independent dataset while standard metabolic 
pathways fail to do so, testifying on the robustness and utility of the metabolic 
features learned by MCF.  
 
Meta-learning is of great relevance to cancer classification as it can potentially 




processes, by taking knowledge on relations between genes and pathways into 
account in the classifier 24,115,116. However, recent studies have reported that 
many of these methods do not outperform a model trained over single gene 
features 25–27,117. MCF offers a solution to some of the main issues that 
hampered previous methods. First, some previous studies are based on pre-
defined gene sets 118 or networks 119 characterizing healthy cells while cancer 
may rewire many functions, and in particular its metabolism. To this end, 
MCF performs unsupervised pathway generation and selection that captures 
key metabolic alterations occurring in cancer. Second, some studies relied on 
the topology of a pre-defined biological network such as a co-expression 
network 119, cellular pathway map 120 or protein–protein interaction (PPI) 
network 121 that have been inferred from high-throughput studies. In 
difference, MCF relies on a manually curated metabolic network that is 
extensively supported by experimental evidence 10. The metabolic network is 
thus less noisy, while still highly informative due to metabolism’s role in 
cancer growth and development. Third, it has been shown that structural and 
directional information improves the predictive power of meta-features over 
single genes 117; In accord, the metabolic network is directional and highly 
structured which allows MCF to infer pathways of biological relevance.  
 
While metabolic reprogramming is a substantial part of cancer biology, the 
methodological insights obtained from developing MCF are general, and 




other cellular networks. This could lead to stronger predictors based on 
reliable models of signaling and regulatory networks on a genome scale. 
Second, finding the most separating paths in differently weighted graphs is an 
NP-complete problem. Here, we only offer a heuristic solution that is 
obviously sub-optimal. This could be improved upon by employing more 
exhaustive and/or efficient weighted path searching methods. We can expect 
that follow-up work will advance the identification of top separating pathways 
in differentially weighted metabolic graphs, potentially improving the power 











Chapter 3: Cancer immunotherapy treatment modifiers 
Accepted to Nature Medicine as :”Robust prediction of therapeutic response to 






Immune checkpoint blockade (ICB) therapy provides remarkable clinical gains, 
where melanoma is at the forefront of its success. However, only a subset of patients 
with advanced tumors currently benefit from these therapies, while incurring 
considerable side-effects and costs. Hence, constructing predictors of patient’s 
response is of crucial value, and such accurate predictors are yet absent. This is a 
serious challenge due to the complexity of the immune response and the lack of large 
ICB-treated patient cohorts with omics and response data, which handicaps the 
construction of robust predictors that are transferable across different datasets. Here 
we build an immune-centered predictor of ICB-response that utilizes immune 
checkpoints’ transcriptomic relations mediating spontaneous tumor regression. It 
robustly predicts melanoma patients ICB-response and can capture almost all true 
responders while sparing treatment for more than half of the non-responders. It 
achieves an overall accuracy of 0.83 over 11 datasets spanning 297 samples including 
unpublished data, outperforming existing predictors.  
Results 
NB Spontaneous regression and ICB response in melanoma  
We hypothesized that an immune-based predictor of spontaneous regression 
may capture the immune activity and could thus be used more generally to 
predict response to ICB for patients with melanoma. To test this hypothesis, 




transcriptomics data of 108 patients, who include both spontaneously 
regressing (patients considered as low risk NB and with no tumor progression) 
and high risk progressing patients (i.e., without spontaneous regression, 
Methods)123. As we are interested in predicting the response to ICB, we 
focused on 28 immune checkpoint genes collected from literature reports that 
were included in all RNA-sequencing (RNA-seq) datasets available to us. To 
capture the predictive relations based on these immune checkpoint genes, we 
based the NB predictor on pairwise relations between the (normalized) 
expression levels of these genes. Each predictive feature compares the 
expression of two checkpoint genes A and B, capturing a logical relation 
between their transcriptional levels (e.g., A > B). We performed a feature 
selection procedure searching for a subset of these features that best separates 
patients with the spontaneously regressing NB from patients with non-
regressing NB, resulting in 15 most predictive features (Methods). Based on 
these features, the prediction of spontaneous regression of a tumor sample 
from its expression data is simply made by counting the number of predictive 
feature pairs that are fulfilled (true) in that sample. This number, ranging from 
0-15, denotes its IMmuno-PREdictive Score (IMPRES), with higher scores 
predicting spontaneous regression. The resulting predictor obtains an accuracy 
of 0.9 (in terms of the Area Under the Receiver Operator Curve (AUC)) in the 
NB dataset. Reassuringly, examining tumors derived from patients with 
melanoma who were not treated with ICB124, we find that the IMPRES scores 




that of other subtypes (Rank-sum p-value = 9.6E-5 and 0.05 for the test and 
validation datasets, Figure 8A). Additionally, we find that IMPRES is 
significantly and positively associated with higher overall survival in these 
datasets124 (Figure 8B), testifying to its ability to capture immune activity that 
is associated with improved melanoma prognosis in the absence of ICB 
treatment. 
 
We next turned to investigate whether there are similarities between the 
cellular processes mediating the immune response in melanoma and those 
mediating spontaneous tumor regression in NB. To this end, we collected 9 
gene expression and ICB response datasets including patients treated with 
anti-CTLA-4, anti-PD-1 or their combination125–130.  First, we identified 
immune related, Consistently Differentially expressed Pathways (termed 
CDPs) in ICB responders versus non-responders (evaluated separately for 
patients treated with anti-PD-1 or anti-CTLA-4 treatments, Methods). We find 
seven CDPs across all anti-PD-1 datasets and four CDPs across all anti-
CTLA-4 datasets (an overlap which is significantly higher than expected, 
permutation P-value=0.001 for anti-PD1 and P-value=0.03 for anti-CTLA-4 
datasets respectively). Second, we find that the CDPs are also differentially 
expressed in a similar manner in the ‘high immune response’ melanomas 
compared with other subtypes (Binomial P=0.003 and 0.0623 for the test and 
validation sets)124 and in spontaneously regressing vs high risk progressing 




between the features identified in NB and the activity of the CDPs, we 
computed the correlations between the expression ratios of each of these 
features with each CDP expression. As evident from Figure 8D, these 
associations are consistently maintained across the four groups studied (All 






Figure 8. NB regression association with melanoma immune response. (A) 
Boxplots showing IMPRES of high vs low immune response in test and 
validation datasets of non-ICB treated melanoma patients124; p-values are 
computed via a Rank-sum test. (B) Kaplan-Meier survival curves of patients 
with high versus low IMPRES (computed over the combined test and 
validation datasets124). The median IMPRES is used to define the “Low 
IMPRES” and “High IMPRES” subgroups. (C) Upper Panel: Heatmaps 
showing the enrichment P-values for CDPs that are up (orange) or down 
(green) regulated in responders versus non-responders across the anti-PD-1 
(encapsulated in the left rectangle) and the anti-CTLA-4 melanoma 
datasets125,127,128,130 (right rectangle). The lower Panel displays the enrichment 
P-values for these CDPs in high immune response vs other subtypes in non-
ICB treated melanoma, and in spontaneous regression vs non-spontaneous 
regression in the NB dataset. (D) Heatmaps showing the rank correlation 𝜌 
between expression levels of each CDP and each of the IMPRES features 
ratios, computed separately over the anti-PD-1 datasets, the anti-CTLA-4 
datasets, the non-ICB treated melanoma datasets and the neuroblastoma 
dataset. White-colored entries denote non-statistically significant associations. 
 
IMPRES predictor  
We turned to apply IMPRES to predict the responses of melanoma patients to 
ICB treatments, without any further training. To this end, we analyzed 256 




1 or their combination125–130. We first computed the IMPRES of each 
melanoma sample based on its expression data and used that for the respective 
Receiver Operator Characteristic (ROC) classification curves. IMPRES 
achieves an AUC= 0.77 for van Allen et al.125 (anti-CTLA-4); AUC = 0.83 for 
Hugo et al.127 (anti-PD-1); AUC = 0.8 for TCGA SKCM128 (anti-CTLA-4); 
AUC = 0.96, 0.77 and 0.80 for Chen et al126 (on-treatment with anti-PD-1; 
pre-treatment with anti-PD-1 (post-CTLA-4 treatment) and pre-treatment with 
anti-CTLA-4, respectively) and AUC = 0.78 and 0.85 for Riaz et al. (pre- and 
on-treatment with anti-PD-1, respectively)130. A lower performance of AUC = 
0.73 is obtained for Prat et al129 (anti-PD-1), a nanostring dataset with low 
coverage of the IMPRES checkpoint molecules126,129 (Figure 9A).  
 
We further tested the predictive ability of IMPRES in a new unpublished 
dataset in which we carried out RNA-seq of tumor biopsies derived from 41 
samples of patients with metastatic melanoma who were treated with different 
ICB therapies at the Massachusetts General Hospital (Methods). IMPRES 
achieves an AUC of 0.81 and 0.97 on the anti-PD-1 and anti-CTLA-4 samples 
respectively (Figure 9B). Evaluating the predictive accuracy of IMPRES on 
the aggregate collection of all the datasets studied above (a total of 297 
samples), IMPRES obtains an AUC of 0.83, significantly superior to all other 
existing published predictive signatures, as shown in detail further below. Its 
aggregate performance is AUC=0.84 on all anti-PD-1 treated samples and 




the potential translational impact of IMPRES, Figure 9C shows the number of 
true/false positives (responders) and true/false negatives (non-responders) 
obtained on this aggregated data at different IMPRES score thresholds. In 
total, there are 89 samples labeled as responders (considered ‘positive’ in the 
classification) and 208 non-responder samples (considered ‘negative’) across 
all datasets.  If one adopts a very conservative approach and predicts 
responders only if their IMPRES score is greater-than/equal-to 12, few such 
predictions arise but all of them are true (top row pair). At a more relaxed 
threshold of 8, IMPRES correctly captures almost all true responders, while 
misclassifying less than half of the non-responders (that is, sparing 
unnecessary treatments for the majority of non-responding patients). When 
further decreasing the classification decision threshold more samples are 
predicted as responders, manifesting the known tradeoff between precision 
and recall (Figure 9D). A qualitatively similar picture emerges when 
considering the anti-PD-1 and anti-CTLA-4 treated patients separately. Higher 
IMPRES scores are also associated with improved overall survival and 
progression-free survival (PFS) in ICB treated melanoma patients (Methods, 







Figure 9. IMPRES performance. (A) Receiver Operating Characteristic (ROC) 
curves quantifying IMPRES prediction AUC across numerous publically 
available ICB response datasets125–130. (B) ROC curves for an independent 
dataset of ICB response (with 10 patients treated with anti-CTLA-4 and 31 
patients treated with anti-PD-1) and for the aggregate datasets including all 
297 samples, the 216 samples of patients treated with anti-PD-1 and 81 with 
anti-CTLA-4. (C) Bar plots showing the prediction accuracy and error types 




‘responder’ prediction) on the aggregate compendium of 297 patients included 
in all 11 datasets studied. The dashed line represents the total number of 
responders. (D) Precision/recall evaluation of IMPRES on the same aggregate 
compendium. The Y-axis displays the precision/recall as a function of the 
number of ‘responder’ predictions made (shown on the X-axis, obtained by 
decreasing the classification threshold, whose value is also displayed in italic 
font). (E)-(F) Kaplan Meier survival curves for the Van Allen et al and Riaz et 
al. ICB treatment datasets, respectively, with high vs. low IMPRES scores 
(using the median IMPRES as a threshold differentiating between the high 
and low groups). (G)-(H) Boxplots showing progression free survival for low 
vs. high IMPRES in the Van Allen and Prat et al. ICB datasets (using the 
median IMPRES as a differentiating threshold).  
 
We next turned to compare the predictive accuracy of IMPRES with that of 
current state-of-the-art predictors. Even though there is a clear association 
between the tumor’s mutational load and patient’s response to ICB, the 
resulting predictive power is fairly moderate, with AUCs in the range of 0.6-
0.7127,131–133, and similarly for predictors based on the neoantigen 
landscape125,131,134,135. Studies based on transcriptomic signatures have 
reported AUCs in the range of 0.6-0.8127,136, but these performance levels are 
mainly limited to the single dataset that was used for their construction. To 
perform the comparison, we built predictors of response to ICB based on each 




IMPRES is significantly superior to each of the other predictors (Paired Rank-
sum test P-value<0.004) (Figure 10A). This observation holds true when we 
compared the performances for each ICB-treatment group separately (Figure 
10B). Compared to IMPRES, the second best predictor, cytolytic-activity 
estimation137, has an overall AUC of 0.68, and that of each of the other 
methods 0.6 or lower. Overall, the predictors built on biologically motivated 
scores (cytolytic-activity137 and PDL-1 expression) generalize better than the 
machine learning based predictors constructed on transcriptomic signatures 
identified in isolated, specific cohorts. Of note, while we find a significant 
correlation between IMPRES and abundances of CD8+ and CD4+ T cells 
inferred via CIBERSORT, the inferred abundances of immune cells 
themselves are poor predictors of response to ICB. IMPRES superiority is 
particularly notable because for most existing signature-based predictors (all 
but cytolytic-activity137 and PDL-1 expression) we had to re-train the latter 
separately for each dataset, otherwise their overall performance was dismal, 
testifying to their poor generalizability between different datasets (Methods). 
In contrast, IMPRES is constructed only once from the NB data and never 
trained on any melanoma dataset; thus, it is markedly less prone to over-
fitting, a paramount concern regarding standard cancer transcriptomics 
predictors138–140. To further study the importance of training on the 
independent NB data, we trained ICB response predictors based on melanoma 
data instead of NB, following exactly the same representation and training 




prediction performances on the melanoma datasets that were not used for 
training compared with those achieved with the original IMPRES procedure. 
For completeness, we additionally compared the performance of IMPRES to 
all other predictors but excluded patients annotated with ‘stable disease’ from 
the analysis. This results in an overall similar picture of superior performance 
of IMPRES versus the other classifiers with a slightly improved performance 
in both. 
 
The features composing IMPRES uncover a few insights that are biologically 
interesting. Reassuringly, the relatively higher expression of known immune 
stimulatory genes (such as HVEM, CD27 and CD40) is associated with a 
better response, while the higher expression of known immune inhibitory 
genes (such as CD276, TIM-3, CD200 and VISTA) is associated with a worse 
response to ICB, as expected (Figure 10C). Higher expression of CD40 
compared to that of PD-1, PDL-1, CD80 and CD28 is associated with a better 
response to ICB, in line with the recent findings that agonists of CD40 reverse 
resistance to anti-PD-1 therapy, and that induced PD-1 expression mediates 
acquired resistance to antagonist CD40 treatment141. Additionally, the higher 
expression of the immune stimulator CD27 compared to that of PD1 (but not 
compared to CTLA-4) is associated with improved response. This is in line 
with recent findings that the combination of a CD27 agonist plus anti-PD-1 




combination of a CD27 agonist plus anti-CTLA-4 did not improve tumor 
control142.  
 
We further studied the individual predictive power of each of the 15 IMPRES 
features, by considering the expression ratio of each predictive pair 
(Methods). We find that some features are specifically more predictive for 
anti-PD-1 pre-treatment (CD28/CD86, Rank-sum P-value = 0.05) or on-
treatment (PD1/OX40L, CD86/OX40L and CD86/CD200, Rank-sum P-value 
= 0.018 for all). Notably, no feature emerges as being strongly predictive of 
response to anti-CTLA-4 specifically (Figure 10D). Next, we examined all 
possible associations between these 15 features (using their expression ratio) 
and the abundance of all 22 types of immune cells inferred by CIBERSORT 
in the datasets of melanoma treated with ICB. Notably, we find two 
significant associations (Bonferroni-Corrected for multiple comparisons,  𝛼 =
0.05) between CD8+ T cells abundance and IMPRES features that hold across 
melanoma datasets: the first involves a significant and consistent negative 
correlation with the CD40/PD-1 expression ratio and the second involves a 
positive correlation with the PD1/OX40L expression ratio (Figure 10E). 
Finally, a feature reduction analysis shows that the overall predictive 
performance of IMPRES can be maintained with a subset of 11 of the 15 






Figure 10. IMPRES features. (A) Bar plot comparing IMPRES performance to 
that of other published approaches across 9 publicly available ICB treatment 
datasets. The performance obtained by each approach is displayed via four 
bars, each representing the AUC for a specific treatment group, with the 
rightmost bar denoting the overall performance across all samples. The Rank-
sum P-values comparing the performance of each classifier evaluated to that 
of IMPRES over all samples are presented (P-value of 0.002 is achieved when 
IMPRES AUC is larger than that obtained by the other predictor for all 9 
datasets, and 0.004 when it is larger for 8/9 datasets). (B) A table showing the 
empirical P-values comparing IMPRES performance to that of each of the 




aggregate of all datasets (the value of ‘<1e-3’ denotes that IMPRES’ 
prediction performance was superior to that of the predictor with which it was 
compared in all 1,000 sampled test repetitions). (C) A network representation 
of the 15 pairwise features comprising IMPRES. Each node represents an 
immune checkpoint gene and each edge describes a pairwise relation (an 
IMPRES feature). The direction of edge A -> B denotes that the higher 
expression of A vs. that of B is associated with better patients’ response. The 
color of the outline of each node denotes if it is inhibitory or activating and its 
fill color denotes whether it belongs to the PD1 or CTLA-4 pathways. (D) 
Clustogram of the individual predictive power of the 15 IMPRES features 
(based on their expression ratios) in each of the melanoma treatment datasets 
studied (the color scaling denotes the AUC obtained using each individual 
ratio as a response predictor, ranging from 0 to 1). (E) Scatter plots showing 
the correlation between CIBERSORT-inferred CD8+ T cells abundance (X-
axis) and the gene expression ratios of two IMPRES features that are 
significantly associated with it (Y-axis); CD40/PD1 (upper panel) and 
PD1/OX40L lower panel). The Spearman 𝜌 and associated P-values are 
shown for each ICB response data125,127,128,130 individually and for all four 
datasets together (excluding nanostring datasets in which low coverage 







Collection of immune checkpoint molecules 
To build a predictor based on pair-wise relations between checkpoint genes’ 
expression, we formed a list of 45 immune checkpoint genes with known co-
stimulatory or co inhibitory effects, collected from literature reports 143–146. 
From these, we focus on 28 genes that were measured in all RNA-sequencing 
datasets analyzed in this paper. 
 
Feature selection and IMPRES construction on the NB data 
For feature selection, we use the quantile-normalized expression of the 28 
immune checkpoint genes selected above in the 108 NB tumor samples 
studied, using the following expression function of pairs of checkpoint genes 
as features: 
 
 𝐹!,!(x)   =




Where 𝑒𝑥𝑝! 𝑥  and 𝑒𝑥𝑝! 𝑥  denote the expression of genes 𝑖  𝑎𝑛𝑑  𝑗 in sample 
𝑥. 
We focus on pairs where at least one of the genes is among the six genes that 
are directly associated with anti-CTLA-4 and anti-PD1 blockade therapy, 
including CTLA-4, CD28, CD80/CD86, PD-1 and PD-L1<sup>147</sup> 
(Buchbinder & Desai, 2016)(Buchbinder & Desai, 2016)(Buchbinder & 




gene pairs. To select features that best separate positive from negative samples 
in the NB data, we performed a hill climbing aggregative feature selection 
involving 500 iterations of a five-fold cross validation procedure, where the 
features that highly scored consistently across folds were selected for 
IMPRES.  
 
Immune pathway enrichment analysis  
To identify CDPs (consistently differentially expressed immune pathways in 
melanoma ICB responders), we first identified the genes that are up and down 
regulated in ICB responders vs non-responders for each of the 
datasets125,127,128,130 (using one sided Rank-sum P-value<0.05). Then, we 
performed a GO pathway148 enrichment analysis for immune related pathways 
via a hyper-geometric test, to identify (1) pathways that are consistently up or 
down regulated (hyper-geometric P-value<0.05) in responders for all anti-PD-
1 melanoma datasets, and  (2) pathways that are consistently up or down 
regulated in responders for all anti-CTLA-4 melanoma datasets (Figure 8C).  
 
To correlate CDPs with the IMPRES features, we then evaluated the 
Spearman rank correlation coefficients (𝜌) and corresponding P-values 
between the median pathway expression level of each CDP (using the median 
expression of all genes in a pathway) and each of the IMPRES expression 
ratios. This is done across all samples in each of the following datasets: (1) the 




datasets (3) the non ICB-treated melanoma datasets and (4) the neuroblastoma 
dataset. 
 
Computing IMPRES features’ expression ratio  
To evaluate the predictive performance and functional associations of 
individual IMPRES features in a more refined manner we used the expression 
ratio instead of the binary indicators in each sample (i.e. for each feature A>B 
we used A/B instead). The resulting AUCs obtained with each ratio feature for 
each ICB response data are presented in Figure 10D. 
 
Applying IMPRES to predict ICB response of melanoma patients 
To apply IMPRES, we calculate for each sample x, the 𝐹!,!(x) over the 15 
IMPRES checkpoint pairs (features). This leads to a binary vector of length 15 
for each sample. The total number of ‘1’s in this vector denotes the sample’s 
IMPRES score (ranging between 0 and 15). High scores predict good 
response. By varying the classification threshold over the different possible 
IMPRES score values we generate the ROC curves and the resulting AUCs 
presented in the main text for each melanoma dataset.  
 
Unpublished data collection and preparation  
RNA-sequencing of 31 anti-PD-1 pre- and on-treatment tumor specimens, and 
10 anti-CTLA-4 pre- and on- treatment tumor specimens derived from 




Jenkins et al149. These patients were enrolled in clinical trials at Massachusetts 
General Hospital. Clinical trial registration numbers at ClinicalTrials.gov are 
NCT01714739; NCT02083484; NCT01543698; NCT01072175; 
NCT00949702; NCT01783938; NCT01006980. 
 
Clinical response classification  
Table 4 enclosed by summarizes the response annotations and criteria used for 
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Kaplan Meier survival analysis 
Kaplan Meier analysis is performed by comparing the survival of patients 
with high IMPRES scores (> median(IMPRES)) to those with low IMPRES 
scores (< median(IMPRES)) using a log-rank test. The patients with median 
IMPRES score (= median(IMPRES)) are grouped with the smaller-size group 




In summary, IMPRES’ high predictive performance is mainly due to two key 
conjectures: (a) key immune mechanisms underlining spontaneous regression 
in NB can predict response to ICB, and (b) specific pairwise relations of 
immune checkpoint genes’ expression can be predictive of spontaneous 
regression of NB and response to ICB in melanoma. Our results demonstrate 
that building on these assumptions leads to a predictor of response to 
checkpoint therapy that is significantly superior to the state-of-the-art and 
displays robust performance across many different melanoma datasets. From a 
translational standpoint, we show that IMPRES can correctly capture almost 
all true responders while misclassifying less than half of the non-responders, 
sparing unnecessary treatments for non-responding patients. Future studies are 
warranted to further study the predictive performance of the approach 




Chapter 4: Cancer chemoradiotherapy treatment modifiers  
 
Prediction of patients with complete pathological response to chemo-radiation 
therapy (CRT) and identification of targets that modulate patients’ response and 
mitigate resistance to CRT 
Introduction 
Rectal carcinomas account for approximately 20% of all colorectal cancers. Patients 
with stage II and III rectal carcinoma are treated with chemo-radiotherapy (CRT) 
before surgery to reduce the rate of local recurrences. However, not all patients 
respond equally well to CRT, with response ranging from complete response, i.e., no 
tumor cells left (Approximately 15-27% of patients (Sanghera, Wong et al. 2008, 
Maas, Nelemans et al. 2010)), to primary resistance. Clearly, accurately predicting the 
response to CRT before treatment commences would be immensely useful: patients 
with a predicted complete response and having other comorbidities might be spared 
surgery. Alternatively, patients whose tumors are resistant could be treated to increase 
sensitively to CRT. Our goal is to build a predictor that will predict complete 
response to CRT based on gene expression data characterizing the tumor of each 
individual patient. This analysis will also reveal the set of discriminating genes and 
accompanying molecular features that play a key role in modulating the response to 
CRT in rectal cancer and will enable identification of targets that play a role in 







Identification and cross validation 
To avoid over-fitting we first performed a feature selection procedure using 
only small number of randomly selected samples (20% of the data). To this 
end, we randomly select eight positive (5% of the patients, Tumor 
Regression Grade (TRG) = 100%) and eight negative (5% of the patients, 
Tumor Regression Grade (TRG) < 45%) cases and search for differentially 
expressed transcripts between these samples, from which to selected the 
features for the classifier. To reliably identify complete responders, without 
misclassifying partial responders, we aimed to select features that will 
maximize the sensitivity of the generated classifier. Therefore, we randomly 
select a second set of 8 positive and 8 negative samples and performed a hill-
climbing procedure 152,  gradually adding transcripts from the group of 
differently expressed transcripts, that improve the sensitivity of a resulting 
SVM classifier, when applied to the second group of samples. A signature of 
42 transcripts resulted in a classifier with maximal sensitivity on the 16 
randomly selected test samples. The resulting classifier generated from 42-
transcript signature was than assessed through a five-fold cross validation 
procedure on training set comprising 32 positive (TRG = 100%) and 32 
negative (TRG < 45%) cases. The cross validation procedure resulted in a 
sensitivity of 0.46 (when allowing zero false positives), AUC of 0.86 and an 
Accuracy of 0.8 (Figure 11A). Based on these 64 cases, an SVM machine was 




Encouragingly, we found that when applying our classifier to the entire data, 
we get a sensitivity of 0.31, AUC of 0.97 and an Accuracy of 0.86 (Figure 
11B-C), indicating that even when considering the full range of TRG (10-
100%), our classifier can correctly identify more than 30% of the complete 
responders with no errors, using a group of 42 transcripts (36 unique genes). 
 
 
Figure 11. Cross validation performance. (A) and (B) Receiver operating 
characteristic (ROC) curve for the cross validation procedure and for the full 
set of 161 patients, respectively. The dashed line represents the objective of 
the rate of true positive sample when the false positive is zero. (C) A heatmap 
showing the 42-gene signature for all 161 patients, sorted by TRG of these 
patients. 
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Validating with an independent datasets 
A major issue impeding the emergence of local advanced rectal cancer 
prognostic or diagnostic tools from molecular signatures is that these 
signatures are often found not reproducible when applied on independent 
datasets (Conde-Muino, Cuadros et al. 2015). To prove this point, we first 
applied our classifier on an independent test that was completely left out to 
this point, including 14 samples from which 4 are complete responders. Our 
classifier results in a sensitivity of 0.25 (when allowing zero false positives), 
AUC of 0.6250 and an Accuracy of 0.785 (Figure 12A-B) 
Next, we tested several recently published classifiers on our data set 
consisting of 161 patients and an independent data set from (Millino, Maretto 
et al. 2017). We find that none of these signatures show a predictive signal 
when applied to our or the data from Millino et al. 
In contrast, when applied to the same independent dataset from of 0.82 and an 
Accuracy of 0.84 (Figure 12C-D), indicating that even when applied on a 
completely independent dataset, our predictor can accurately foresee 25% of 





Figure 12. Performance for two independent datasets. (A) A heatmap showing 
the 42-gene signature for the 14 patients in our test set (B) Receiver operating 
characteristic (ROC) curve resulting from applying our classifier to the left-
out test set. (C) A heatmap showing the 42-gene signature for the 38 patients 
in the dataset from (Millino, Maretto et al. 2017), sorted by TRG of these 
patients. (D) Receiver operating characteristic (ROC) curve obtained by 
applying our classifier on independent dataset with 38 patients. The dashed 
line represents the objective of the rate of true positive sample when the false 
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Colorectal cancer patient survival prediction 
Patient complete response (pCR) is associated with an improved survival and 
a more favorably oncological outcome. We therefore hypothesized that due to 
their biological function; the expression patterns of genes in the classifier 
predicting pCR in rectal cancer patients should be also associated with good 
prognosis. To this end, we calculated a patient specific score using the 42 
genes in the selected signature. For each gene, 𝑔 ∈ 𝐺!"# is defined if its 
expression is increased in responder samples in the training set, and 𝑔 ∈ 𝐺!"# 
is defined if its expression is increased in resistant samples in the training set. 
The score of each patient is then defined by, 





As expected, we find significant correlation between these scores and Tumor 
regression grade (rho = 0.3398, Spearman p  = 1.03e-05, Figure 13A). We 
then calculated this score for each patient in the TCGA (Cancer Genome Atlas 
2012) colorectal cancer database (n=276) and in a second dataset from  
(Jorissen, Gibbs et al. 2009) colorectal cancer (n=290). Strikingly, we find 
that high score is significantly associated with improved survival (Log-rank 
p=0.0051 and 0.021, respectively. Figure 13B-C). This testifies further on the 






Figure 13. Patients score of response to CRT predicts survival in two 
independent datasets of colorectal cancer. (A) A scatter plot showing the 
correlation between the tumor regression grade in percent (X-label) and the 
gene signature score assigned to each patients representing predicted response 
to CRT (Y-label). (B) and (C) are the Kaplan-Meier survival curves for 
colorectal cancer patients predicted by using this score to have the best and 
worst prognosis (top and bottom 10% of patients scores, respectively; 
Methods) in the TCGA database and data from 153 
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Chapter 5: Monogenetic disorders modifiers 




Substantial clinical variability is observed in many Mendelian diseases, so that 
patients with the same mutation may develop a very severe form of disease, a mild 
form or show no symptoms at all. Among the factors that may explain these 
differences in disease manifestations are modifier genes 154. Identifying these genetic 
modifiers may be of great interest from both treatment and genetic counseling 
perspectives 155. However, very few modifier genes have been identified so far and 
the mechanisms underlying clinical variability of Mendelian disorders remain poorly 
understood, mainly due to the low frequency of the mutations causing these disorders 
and the scarcity of available data.  
 
Strategies used to show the role of genetic factors in phenotypic expression are often 
classified into three categories depending on the type of data available 38: (1) 
Association studies of case-control data, which is the most widely used strategy in the 
search for modifier genes, probably as it requires sampling patients only, rather than 
collecting familiar data. In association studies, the distribution of marker genotypes is 
compared in patients with different levels of the phenotype. (2) Linkage studies, 
which require available data from affected siblings. Linkage analysis compares the 
number of alleles shared identical by descent by affected siblings between 




genome-wide screens, which consists in searching for the genetic factors involved in 
the phenotype of interest over the whole genome, to identify individuals that are 
resilient to mutations causing the phenotype of interest. 
 
Here we present an approach for genome-wide GENtic moDULators identiFication 
(GENDULF) that is applicable in the lack of large DNA sequencing data. GENDULF 
operates by mining tissue gene expression of healthy and disease bearing individuals 
to identify expression patterns of genes that may modify disease severity. We first 
apply our approach to identify tissue specific modifiers of Cyctic Fibrosis (CF), for 
which considerable efforts has already been invested to find genetic modifiers. 
GENDULF prioritize most of the modifiers previously identified for CF in both lung 
and colon tissues (via linkage and association studies), and points to a few new 
candidates that may potentially bear a modifying role. To experimentally validate our 
approach, we then apply it to Spinal Muscular Atrophy (SMA), for which fewer 
modifiers have been previously discovered.  We find one gene, U2AF1, out of four 
candidates arising initially, that consistently increases the ratio between full length 
SMN2 to ∆7SMN2, thus potentially increasing the levels of the SMN protein and 
improving the phenotype for SMA patients.  
Results 
GENDULF pipeline 
We set to search for genes that modify the phenotype associated with a 




regulation would result with a healthier phenotype, as these may have 
therapeutic value if targeted by drugs. GENDULF is based on the notion that 
modifier genes may be active in healthy individuals where a gene that is 
causing a monogenetic disorder (termed GCD) is lowly expressed, but that 
these are probably inactive in disease bearing individuals. Based on this 
rational, GENDULF proceeds in two main steps (Figure 14): (1) First, for a 
given monogenetic disorder studied, we identify Potential Modifiers (PMs) 
which are genes that are particularly lowly expressed when the GCD is lowly 
expressed in the relevant tissue for the disease. This association may 
potentially underlie the rescued phenotype observed when the GCD is inactive 
in healthy individuals. (2) Then, we identify Disease associated PMs (DPMs). 
To this end, we examine the expression of the PMs in studies containing both 
diseased and control samples. We hypothesize that if a gene is a genetic 
modifier whose low expression confers a healthy phenotype (as indicated by 
the first step) then we should expect to find it highly expressed in disease 
samples, which evidently are not rescued (i.e. DPM). This is in 
contradistinction to genes that are co-expressed with a gene causing a 
monogenetic disorder in healthy tissues but are not genetic modifiers, whose 
expression should remain correlated with that of the GCD also in the disease 





Figure 14. An overview of GENDULF computational pipeline. (1) Mining 
transcriptomics of healthy tissues afflicted by a disorder to identify PMs. (2) 
Evaluate the expression of the PMs in studies containing both diseased and 
control samples to find DPMs genes that are not co-expressed with the GCD 
in disease tissues. 
Cystic Fibrosis 
Cystic fibrosis (CF) is an inherited disorder that causes thick, sticky mucus to 
form in the lungs, pancreas, colon and other organs. In the lungs, thick mucus 
can damage tissue and block airways, making it difficult for patients to 
breathe and promoting lung infections 156. CF is caused by mutations in the 
CFTR gene result in defective cystic fibrosis transmembrane conductance 
regulator (CFTR) proteins 157,158. Normally, CFTR proteins located on the 
surface of the epithelial membrane act as chloride channels that in turn 
Healthy GTEx tissues
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regulate the epithelial sodium channel and other anion channels at the cell 
surface. The complex interplay of these channels regulates the electrochemical 
gradient that allows appropriate airway surface liquid depth and mucus 
viscosity 159,160. CF affects 60,000 individuals worldwide and is a good model 
for the identification and characterization of factors that influence disease 
variation as its high prevalence provides a large number of accessible patients 
to perform detailed phenotypic analyses 161,162. So far a few modifiers has 
been identified for CF lung disease severity through association studies 162,163. 
We hence set to identify tissue specific CFTR modifier and compare our 
findings against these recently identified genetic modifiers. 
We First applied GENDULF to analyze 320 healthy lung samples from the 
GTEx database, which yielded 55 PMs. We then examine the expression of 
these genes in nasal brushings of the inferior turbinates of mild and sever CF 
patients and healthy controls 164. We find that the while the CFTR gene 
expression generally decreases in mild and severe CF patients vs. controls, the 
expression of the 14 of the PMs increases in severe CF (Figure 15A), 
testifying to their potential modifying role.  
Reassuringly, some of the CFTR modifiers identified in lung tissues are 
known modifiers of CF manifestations in the lung, including the EHF gene, a 
known modifier gene of lung disease severity in CF 162 and SLC6A14, which 
has been recently identified as potential modifier of lung disease severity in 





Second, we applied GENDULF to analyze 345 healthy colon samples from 
the GTEx database, yielding 11 candidate genes. Examining the expression of 
these genes in rectal mucosal epithelia from CF patients and healthy controls 
165, we find that the expression levels of four of these candidates is higher in 
CF than in normal control samples, thus all predicted as CF genomic 
modifiers in the colon (Figure 15B). Interestingly, the knockdown of one of 
the four identified modifiers, FABP1, rescues a lethal intestine defect in 
mouse model of CF 166  
 
A recently published study 163 has pointed to five loci that display significant 
association with variation in CF lung disease. The identification of a gene that 
causally affects disease variation is challenging as such association loci may 
typically include many genes 38. We applied GENDULF to evaluate the genes 
within these five loci to identify candidate modifiers of CF lung disease 
severity.  
To this end, in a given loci, for each gene we evaluated the level by which its 
expression is significantly down regulated when the expression of CFTR is 
extremely low in healthy lung tissues, quantified via a Wilcoxon rank-sum P-
value. We find that in four of the five loci we studied (all but chr5p15.3) at 
least one gene is showing such a significant functional association (FA) and 
that the level of these FAs varies monotonically with the genomic location of 
the gene (it is gradually increasing up to a maximum and then gradually 




varying FAs does not occur in random, as it is never obtained when analyzing 
randomly shuffled CFTR expression values. This, it is likely that these 
ordered monotonic expression patterns truly capture FAs with the CFTR gene. 
Furthermore, notably the modifier genes of CF pointed by the authors of 162,163 
mostly fall at maxima points, as shown in Figure 15C, including EHF, MUC4, 




Figure 15. CF identified modifiers. (A) CF identified modifiers expression in 
healthy lung for high vs. low CFTR expression (left panel) and in severe CF, 
mild CF and healthy controls. (B) CF identified modifiers expression in 
healthy colon for high vs. low CFTR expression (top panel) and for CF and vs 
controls (bottom panel). (C) The p-values assigned to genes within chr11p12-
p13, chr6p21.3, chr3q29 and chrXq22-q23 ordered by their location. The 


















































































































































































































































































































evaluated genes and the upper dashed line represent a significant threshold 
corrected for all genes and transcripts in GTEx with alpha = 0.05.  
 
  
Spinal Muscular Atrophy  
Spinal muscular atrophy is an autosomal recessive neurodegenerative disease 
characterized by degeneration of spinal cord motor neurons, atrophy of 
skeletal muscles, and generalized weakness. SMA is caused by deletion or 
mutation of the survival of motor neuron 1 (SMN1) gene, which encodes the 
SMN protein 167,168. Humans carry two paralogous SMN1 and SMN2 genes 
that are ubiquitously expressed. The SMN protein is principally produced 
from SMN1 full-length mRNA, as SMN2 transcripts often goes through 
alternative splicing and exclusion of exon 7, resulting in mRNA that encodes 
an unstable SMN protein that is rapidly degraded 169,170.	  However, the low 
levels of SMN2 transcripts still produce small amounts of the fully functional 
SMN protein. 
Here, We use healthy Muscle and Spinal cord tissues, in which SMN1 
expression is considerably variable; to evaluate the expression of different 
SMN2 isoforms when SMN1 is especially low. In both tissues we find 
increased full-length SMN2 transcript levels when SMN1 expression levels 
become very low (Spearman Rho = -0.1427, -0.1432 and Rank-sum p-value = 
1.3657e-05 and 0.084, for healthy muscle and spinal chord tissues, 




indeed in play in healthy tissues when SMN1 expression is very low, thus 
investigating the trascriptomic changes occurring in such healthy samples may 
reveal other GM of SMA, whose alterations may modify SMN levels in 
diseased tissues as well.  
Hence, we applied GENDULF to find genetic modifiers for SMA whose 
knockdown (KD) will result in improved phenotype. To this end, we search 
for genes that fulfill all the four following criteria:  
(1) Genes whose expression is significantly lower than expected when SMN1 
levels are extremely low (bottom 10th percentile) in healthy muscle and 
spinal cord tissues, suggesting that their low expression may have a 
compensating affect for the loss of SMN1. 
(2) Genes who’s under activation is associated with higher ratio between full-
length SMN2 levels and exon7 skipped SMN2 levels, testifying for their 
potential compensating affect through reducing the exon7 skipping of 
SMN2. 
(3) Genes whose expression is not reduced by the KD of SMN1 (to simulate 
the SMA disease state, in either in iPSC-derived motor neurons or human 
SH-SY5Y cells). This indicated that the observed association between 
these genes and SMN1 in healthy tissues is not due to mere co-expression 
but may signify a true functional rescue effect in the maintaining these 
tissues as healthy, while the lack of this rescue effect results in an SMA 




(4) Genes whose expression is higher in SMA vs. controls in Muscle or Spinal 
cord tissues, further testifying on a true modifying effect rather than a co-
expression pattern. 
This analysis points to two potential targets that withstand all three criteria 
with sufficient statistical significance, U2AF1 (Figure 16A-E) and 
HNRNPA0.  
Experimentally testing these targets, we find that the top predicted target, 
U2AF1, indeed increases the ratio between the levels of full-length SMN2 





Figure 16. U2AF1 gene. (A) Scatter plots showing the correlation between 
U2AF1 and Δ7𝑆𝑀𝑁2  levels in healthy muscle (upper panel) and healthy 
spinal cord (lower panel) (B) Scatter plots showing the correlation between 
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ρ = 0.36, P = 2e-14
ρ = 0.25, P = 0.04 ρ = -0.13, P = 0.3


















































muscle (upper panel) and healthy spinal cord (lower panel) (C) boxplot 
showing U2AF1 expression in healthy muscle (upper panel) and healthy 
spinal cord (lower panel) for samples with high vs. low SMN1 expression (D) 
Boxplot showing the expression of the two U2AF1 transcripts in controls vs. 
SMN1 shRNA in human SH-SY5Y cells (upper panel)  and iPSC-derived 
motor neurons (lower panel). (E) Boxplots showing U2AF1 expression in 
controls vs. SMA in muscle (left panel) and spinal cord (right panel) (F) 
Experimental testing the affect of U2AF1 KD on full length SMN2, ∆7 SMN2 
and the ratio between full length SMN2 and ∆7 SMN2. 
***Figure 16F and the work presented in it is generated by Charlotte Sumner 






We present GENDULF, a novel systematic approach to identify generic 
genetic modulators for monogenetic diseases. GENDULF identifies 
expression patterns of genes that may modify disease severity using gene 
expression of healthy and disease bearing individuals, and it is the first 
approach for modifiers identification that is applicable in the lack of large 
DNA sequencing data. We first validate GENDULF in Cyctic Fibrosis (CF), 
where we show that it prioritizes most of the modifiers previously identified 




Additionally, we validate GENDULF in Spinal Muscular Atrophy (SMA), 
where we identify U2AF1 gene, which, as predicted, consistently increases 
the ratio between full length SMN2 to ∆7SMN2.  
 
GENDULF may be applied to a spectrum of monogenetic diseases to 
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